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In post-menopausal breast cancer, obesity is related to invasive tumours that are 
resistant to chemotherapy and have a poor outcome. Recent research has revealed that 
adipocytes co-cultured with breast cancer cells (cancer-associated adipocytes or CAA) 
exhibit a decrease in late adipocyte differentiation markers, and increased expression 
of adipokines and extracellular matrix proteins such as collagen. In the breast tumour 
microenvironment collagen has been shown to exert a pro-tumorigenic influence by 
altering the tumour microenvironment to facilitate metastasis, and by acting as a ligand 
to stimulate breast cancer cells to undergo epithelial-mesenchymal transition (EMT).  
Therefore, the overall aim of this study was to investigate the role of the CAA-collagen 
axis in human breast carcinoma specimens. Specific objectives included (1) 
determining the number and size of CAA at the invasive margin and within the tumour, 
(2) identifying the patterns of collagen deposition and alignment near CAA and within 
the tumour, (3) determining the relative levels and localisation of markers of breast 
cancer cell EMT, and (4) analysing this experimental data together with tumour 
pathology and patient clinical data. 
The study cohort comprised 46 post-menopausal (aged 51yr+) women with invasive 
breast carcinoma, with formalin fixed paraffin embedded (FFPE) tumour samples and 
at least five years follow-up data available via the Cancer Society Tissue Bank 
Christchurch (CSTBC). Four patient groups were included: (1) Oestrogen receptor 
positive (ER+), Body Mass Index (BMI)=20-24.9 (n=11); (2) ER+, BMI>30 (n=12); 
(3) hormone receptor negative/triple negative breast cancer (TNBC), BMI=20-24.9 
(n=10); and (4) TNBC, BMI >30 (n=13). The tumour samples were characterised by 
their clinicopathological parameters including histological subtype, Nottingham 
Prognostic Index (NPI), tumour size, tumour grade, lymph node status, stage and 
ER/PR/HER2 status. H&E stained tumour samples were assessed for the number and 
size of CAA along the interface and within the tumour, as well as the Tumour-
Associated Collagen Signature (TACS) or pattern of collagen deposition and 
alignment, and these parameters were analysed together with patient 
clinicopathological data (Chapter 2). To investigate whether collagen was acting as a 




analysis was used to determine the pattern of expression of Discoidin Domain Receptor 
2 (DDR2) and markers of EMT (vimentin, Snail1) (Chapter 3). Experimental variables 
from both Chapters were analysed together with patient clinicopathological data 
including disease free survival and overall survival.   
Adipocyte diameter (p<0.001), area (p<0.001), and number (p=0.008) were all 
significantly decreased within the tumour compared to at the tumour interface.  As 
expected, there was strong positive correlation between adipocyte diameter and area at 
both the interface and within the tumour (p<0.01), and both parameters were negatively 
correlated with adipocyte count (p<0.01). Adipocyte count within the tumour was 
higher in grade 3 versus grade 1 and 2 tumours (p=0.22). Adipocyte diameter, area and 
number were not significantly different in tumours with TACS-1/2 versus TACS-3. 
However, Body Mass Index (BMI) was significantly higher in patients with TACS-3 
compared to TACS-1/2 tumours (p=0.044), and this was due to patient weight (p=0.05) 
not height (p=0.94). In tumour sections stained with a pan-collagen stain (Masson’s 
Trichrome), cancer cells appeared to preferentially invade along straightened, aligned 
collagen fibres, which may provide ‘highways’ for intravasation. 
Immunohistochemical analysis showed DDR2 protein was present in mesenchymal 
stromal and immune cells at the tumour interface, but not in breast cancer cells. 
Vimentin was strongly expressed in TNBC samples and showed the expected positive 
correlations with tumour grade (p=0.02) and stage (p=0.07). Vimentin immunostaining 
was negatively correlated with adipocyte diameter (p=0.029) and area (p=0.013) at the 
tumour interface, adipocyte diameter (p=0.032) and area within the tumour (p=0.032), 
and a positive correlation with adipocyte count within the tumour (p=0.05). Snail1 
immunostaining was strongest near the tumour interface and weaker in the centre of the 
tumour. 
Overall, this study confirmed CAA were smaller at the tumour interface and further 
reduced in size within the tumour stroma. High patient BMI and weight were associated 
with increased TACS-3, and both TACS-3 and CAA number within the tumour were 
positively correlated with high grade (grade 3) breast tumours. CAA were often 
surrounded by collagen and were abundant in areas with strong vimentin 
immunostaining at the interface and within the tumour. This study did not provide direct 




ligand to activate DDR2 and promote EMT. However, results from this study indicate 
the value of TACS-3 as a marker of localised invasion and metastasis, and indicate that 
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Chapter 1  
Introduction and Review of Literature 
1.1 Introduction 
Global incidence rates of breast cancer have increased dramatically (Jemal et al., 2011). 
In New Zealand, it has been estimated to be the most commonly diagnosed cancer 
(2,700/annum) and second commonest cause of death from cancer (600/annum) 
(Ministry of Health 2018). Excess adiposity is a negative prognostic factor for all 
women with breast cancer (Chan & Norat, 2015). There is higher mortality rate due to  
distant metastases at diagnosis in obese women, and weight gain during chemotherapy 
is associated with early tumour relapse and decreased survival (Chan & Norat, 2015; 
Cleary & Grossmann, 2009; Jemal et al., 2011; Kamineni et al., 2013; Protani et al., 
2010). 
Emerging evidence suggests that the local (paracrine) effects of adipocytes could 
contribute to this poor outcome (Huang et al., 2011; Khan et al., 2009; Li et al., 2010). 
Breast tumours develop and progress within surrounding adipose tissue (particularly 
post-menopausal breast cancers), and adipocytes are therefore likely to be the first cells 
encountered by invading breast cancer cells (Dirat et al., 2011; Iyengar et al., 2005). 
Recent research has revealed that adipocytes co-cultured with breast tumour cells 
exhibit a decrease in late adipocyte differentiation markers and overexpress 
inflammatory cytokines and proteases. These cancer-associated adipocytes (CAA) 
induce partial epithelial-to-mesenchymal transition (EMT) in breast cancer cells (Dirat 
et al., 2011), and cause breast cancer cells to become more invasive (Dirat et al., 2011) 
and resistant to radiotherapy (Bochet et al., 2011). 
 
Our own unpublished data has revealed CAA secrete large amounts of collagen 
(particularly collagen I) when exposed to breast cancer cells in vitro (Dr Elisabeth 
Phillips, Mackenzie Cancer Research Group). Collagen is known to promote cancer 
cell metastasis by (a) altering the extracellular matrix to facilitate metastasis (Conklin 
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et al., 2011; Provenzano et al., 2006), and (b) by inducing cell signalling pathways that 
activate EMT in invading cancer cells (Valiathan et al., 2012). 
 
Therefore, this study used an immunohistochemical approach to determine the presence 
of CAA in human breast tumours, and to investigate patterns of collagen deposition, 
protein expression and localisation of the Discoidin Domain 2 collagen receptors, and 
markers of breast cancer cell epithelial-mesenchymal transition. These experimental 
data were then analysed together with clinicopathological data to look for correlations 
with tumour pathology and patient outcome.  
1.2 Breast Cancer 
Breast cancer is a significant health burden in women worldwide. French 
epidemiologist Parkin and others have published an overview of global cancer data for 
major cancers in terms of their geographical distributions and various epidemiological 
tools to measure these parameters (Parkin et al., 2005). According to their study (Parkin 
et al., 2005), breast cancer ranked as the third most common cancer in the world 
(796,000 cases in 1996) and also happens to be the most common cancer in women 
(21% of all new cases). Worldwide, mortality to incidence ratio was about 61%, with 
an estimated 314,000 annual deaths representing 14.1 % of cancer deaths in women. It 
was also observed that survival statistics for breast cancer were good, with highest 
crude survival noted in Japan (74%), followed by Australia and New Zealand (68%), 
whereas it was lower in Europe (53-63%) and rest of the world (49-61%). 
Additional studies were performed by the same group investigating international 
variations in the epidemiology of breast cancer incidence and mortality among 
populations in every region; and also between populations over time, especially in the 
context of risk factors as well as preventive strategies (Parkin et al., 2005). It was 
observed that female breast cancer accounted for 1 of 10 of all new cancers diagnosed 
worldwide every year. It was the commonest cancer in women in both developing as 
well as developed areas, with the majority (55%) occurring in the latter regions, where 
age-standardised rates were three times greater than in developing areas. Furthermore, 
an attempt was also made to include migration studies and it was observed that breast 
cancer risk increased markedly, especially if migration occurred earlier in life. This 
pointed towards the role of environmental factors as a putative risk determinant. 
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Overall, the study emphasised the role of primary prevention and early diagnosis as 
preventive strategies for breast cancer. 
Althuis et al. (2005) studied breast cancer statistics and time trends around the same 
time and reported that breast cancer incidence paralleled mortality rates, and varied 4-
fold by geographical location between countries with the highest and lowest rates. In 
agreement with Parkin et al. (2005) incidence and mortality rates remained highest in 
developed as compared to developing countries. This could be attributable to 
differential use of screening mammograms and disparities in lifestyle and hereditary 
factors. However, neither study provided any quantification of the risk determinants 
that require further research. 
1.2.1 Breast Cancer in New Zealand 
Breast cancer is a highly diagnosed type of cancer in NZ women and the second most 
common cause of mortality (Ministry of Health 2011, Cancer: New registrations and 
deaths 2008, Wellington. Ministry of Health). It has a significant burden on healthcare 
with costs estimated at $76.8 million/year. According to Ministry of Health statistics, 
Māori women in New Zealand have among the highest incidence rates known for breast 
cancer worldwide, with an incidence rate that is  28% higher, and a mortality rate that 
is 60% higher as compared to New Zealand European women (Ajwani et al., 2003; 
Robson & Cormack, 2006). 
Four main studies provide additional information to understand ethnic differences in 
the biology of breast cancer in New Zealand. The largest study to date was published 
by McKenzie et al. (2008) by studying a subset of women with breast cancer between 
1994-2004 from the cancer registry of New Zealand. They reported that Māori women 
presented with poor prognosis breast tumours including major differences in 
biological behaviours, as well as increased occurrence of poorly differentiated 
histology. Furthermore, these tumours were associated with HER-2 positive and 
ER/PR negative receptor status. However, these observations were independent of 
socioeconomic status. Another two groups from Auckland and Christchurch also 
studied the ethnic disparities in the biological behaviour of breast tumours in New 
Zealand and made significantly different observations. The Auckland group studied 
all women with breast cancer in the greater Auckland area from 2000 - 2005 and 
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found that NZ Māori and Pacific Island women had larger and higher-grade tumours 
and increased lymph node invasion compared to non-Māori women. However, no 
difference was noted for lymphovascular invasion ( LVI), ER and PR status between 
ethnic groups (Weston et al., 2008). Dachs et al. (2010) studied a subset of breast 
cancer patients from Christchurch and observed that Māori women did not exhibit 
pathological or molecular characteristics predictive of poor prognosis compared to 
their New Zealand European counterparts. This data differs from the Auckland data 
and could potentially be attributed to regional population differences. Seneviratne et 
al. further studied breast cancer biological characteristics and ethnic variations and 
found distinct differences in their findings in comparison with the previous studies. 
They found that Māori women had increased rate of advanced stage, advanced grade 
and likely HER-2 positive cancers. However, no major differences were seen in rates 
of ER/PR negative or Triple negative breast cancer (TNBC) (Seneviratne et al., 2015). 
Although these findings have undoubtedly helped to understand breast cancer biology 
in New Zealand, especially in the context of ethnic disparities, the exact nature of these 
differences need further research. 
Māori breast cancer patients also experience inferior outcomes of cancer treatment as 
compared to NZ Europeans. Māori patients were more likely to undergo mastectomy 
but less likely to undergo breast reconstruction or breast conserving surgery 
(Seneviratne et al., 2017). However, there was no difference in sentinel node biopsy or 
definitive local therapy between Māori and NZ European (Campbell et al., 2015; Hill 
et al., 2010; Stevens et al., 2008). Overall, the rates of all four treatment options were 
comparable with those reported from other nations with comparable health care systems 
(Jack et al., 2013; Rosenberg et al., 2005).  
Urban rural differences in breast cancer have also been shown. Lawrenson et al. (2016) 
found that in New Zealand rural areas women presenting with breast cancer were older 
and more likely Māori. Furthermore, rural Māori women were older with metastatic 
disease compared to urban Māori women and had less chance of being screen detected. 
Also, rural Māori women had poorer survival and all-cause survival at 10 years (72.1% 
and 55.8%, respectively) compared to urban Māori women (77.9% and 64.9%, 
respectively). The study concluded that rural Māori women were the most likely to 
benefit from extra efforts taken for improved health care. 
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The Breast Cancer Quality Audit (BQA) program of the Breast Surgeons of Australia 
and New Zealand has collected data on early breast cancer, treatment and survival for 
1998-2010 (Campbell et al., 2015). In New Zealand, the overall survival rate was 90%; 
survival rate was the highest for NZ European (91%), followed by Māori (87%) and 
Pacific (84%). For more advanced stages, the survival rate was 86% as reported by the 
NZ cancer registry (Jeffreys et al., 2005). These survival differences were attributed to 
the differences in access to services, quality of care and timeliness, presence of co-
morbidities and other biological factors. For example, Māori and Pacific women 
presented at younger ages if they were from low socioeconomic backgrounds and lived 
in rural areas away from the regional cancer centres. In addition, they tended to have 
larger, more aggressive tumours. However, they were less likely to have TNBC 
phenotype. Although several measures have been taken by New Zealand Cancer 
Control Strategy which have led to palpable improvements in the results for cancers in 
Māori patients, it still requires greater efforts as breast cancer inequities persist at 
multiple levels from screening, access to health care facilities and treatment (Campbell 
et al., 2000; Page et al., 2014). 
A recent study attempted to quantify the relative contributions of patient, tumour and 
health care system factors that could contribute to breast cancer survival disparity 
between indigenous Māori and European women in New Zealand (Seneviratne et al., 
2015). They reported that Māori women have a two-fold age-adjusted risk of death from 
breast cancer as compared to New Zealand European women. They further added that 
equity focused health care including increased screening coverage, and equitable 
quality of care in a timely fashion may aid towards bridging this disparity. 
1.3 Obesity is associated with poor outcome in breast cancer patients. 
Obesity continues to be a modern health concern due to its pattern of rising prevalence 
rates (Gilman, 2008), and the current number of overweight and obese individuals 
globally is at an all-time high (Ng et al., 2014). Obesity is a serious problem facing 
New Zealand, which as a country stands among the top five most obese nations of the 
world (OECD obesity update, 2017), with an estimated 30% of New Zealanders being 
overweight and an additional 40% obese (Salmond & Crampton, 2012). Even more 
concerning is that obesity rates in New Zealand are projected to increase further by 
2030 (OECD obesity update, 2017). 
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1.3.1 Epidemiological evidence 
1.3.1.1 Obesity and Cancer 
Arnold et al. (2015) performed a population-based study and quantified the worldwide 
burden of cancer attributable to increased BMI utilizing the GLOBOCAN 2012 data. 
They observed that 3.6% of new cancer cases in adults (aged ≥30 years after a lag period 
of 10 years) in 2012 were attributable to high BMI; corpus uteri, post-menopausal 
breast cancer and colon cancers accounted for 63.6% of cancers attributable to high 
BMI. In numbers, breast cancer accounted for about 1.67 million cancer cases 
worldwide in 2012 (Arnold et al., 2015). The recent advances in breast cancer diagnosis 
have also led to an increased number of breast cancer survivors (Miller et al., 2016; 
DeSantis et al, 2014).  
1.3.1.2 Obesity and breast cancer 
Epidemiological studies from the World Cancer Research Fund have provided evidence 
to establish a causal link between obesity and several human cancers including post-
menopausal breast cancer (Fund & Research, 2007). More specifically, the most 
rigorous meta-analysis to date reported strong associations between excess body weight 
(over-weight, Body Mass Index (BMI) = 25-29.9 kg/m2; obese, BMI ≥ 30 kg/m2) and 
increased risk of a subset of cancers including breast cancer (Renehan et al., 2008). 
Obesity has also been reported to be as an independent risk factor for many cancers 
(AICR, 2008), including post-menopausal breast cancer – especially the ER-positive 
and PR-positive phenotype (AICR, 2008). Interestingly, the same study observed that 
obesity is inversely associated with pre-menopausal breast cancer (AICR, 2008), and 
this supports earlier studies in breast cancer which reported that obese women have a 
higher risk to develop post-menopausal breast cancer compared to premenopausal 
women (Calle & Kaaks, 2004). 
Several anthropometric markers exist that could measure adiposity. For example, Body 
Mass Index (BMI) as a measurement of general adiposity and waist circumference 
(WC) to measure central adiposity, but it is not clear which of these best predicts cancer 
risk. Neuhouser et al. (2015) used BMI as an anthropometric measurement to predict 
breast cancer risk. Secondary analysis of data obtained from the Women’s Health 
Initiative (WHI) clinical trials to further look for associations between obesity and risk 
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of developing post-menopausal invasive breast cancer with an extended follow-up. 
BMI was positively correlated with an increased risk of invasive breast carcinoma 
(P<0.001). They found a strong linear trend where the risk was reported to increase 
across the BMI categories. The strongest associations were seen for women with a BMI 
greater than 35.0; these women had a 58% increased risk of invasive breast carcinoma 
in comparison with women with a BMI lower than 25.0. Mortality from breast cancer 
was more than 2-fold higher in women with grade 2 and grade 3 (BMI >35) obesity in 
comparison with those with normal BMI. A BMI>35 or higher was also strongly 
correlated with increased risk for ER-positive, PR-positive breast cancers, however it 
was not correlated with ER-negative cancers (Neuhouser et al., 2015). Another study 
performed by Harding et al. (2015) included data from 11 cohort groups comprising a 
total of 79,458 subjects from the Australian and New Zealand Diabetes and Cancer 
Collaboration with complete anthropometric information (BMI), waist circumference 
(WC), Hip Circumference (HC), waist to height ratio (WHR) and A Body Shape Index 
(ABSI) obtained from the Australian Cancer Database. It was also observed that BMI, 
WC and HC were correlated with post-menopausal breast carcinoma. The strongest 
association was found for WC, excluding post-menopausal breast cancer where HC was 
found to be the strongest association (Harding et al., 2015). 
In contrast to studies of risk, ongoing research has demonstrated that excess adiposity 
has a negative prognostic factor for all breast cancer patients (Jemal et al., 2011; Protani 
et al., 2010; Kamineni et al., 2013; Ewertz et al., 2010). These studies have revealed 
that about half of breast cancer patients are obese at the time of diagnosis, (Demark-
Wahnefried et al., 1997), are more vulnerable to gain weight (Demark-Wahnefried et 
al., 1997; Vance et al., 2011) and more prone to change of body composition post 
chemotherapy (Sheean et al., 2012). Increased adiposity is linked with worse outcome 
in breast cancer patients including increased risk of recurrence (Chlebowski et al., 
2002), death (Niraula et al., 2012; Protani et al., 2010), development of second primary, 
(Druesne-Pecollo et al., 2012), increased risk of lymphodema (Velanovich & 
Szymanski, 1999), with poor quality of life (Montazeri, 2008) and presence of 
comorbidities like diabetes, hypertension as well as cardiovascular disease (Satariano 
& Ragland, 1994). In addition, obese women <56 years treated with adjuvant 




In New Zealand, Robinson et al. (2017) studied the association between BMI, 
clinicopathological factors and outcomes in a total of 5,458 newly diagnosed breast 
cancer patients using the Canterbury Breast Cancer Registry (Robinson et al., 2017). 
They reported that higher BMI was associated with non-European ethnicity, post-
menopausal status, screen-detection, older age and tumours with higher grade, greater 
size and positive progesterone receptor status. They further reported that mean survival 
for women less than 56 years was 18.0 years for normal BMI and 14.8 years for 
BMI>35.  
Obesity-related diseases, such as Type 2 diabetes and insulin resistance, are also linked 
to increased risk and mortality in breast cancer (Del Barco et al., 2011). About 10% of 
women aged 55-64years (the age range for most early breast cancer patients) have 
clinically diagnosed type 2 diabetes and a further 34% have prediabetes. In New 
Zealand, the prevalence of diabetes and prediabetes in Māori aged 45-64 years is 55%, 
and 41% of adult Māori meet the criteria for obesity (Coppell et al., 2013; Robson & 
Cormack, 2006). These co-morbidities may contribute to the poor outcome in New 
Zealand Māori women diagnosed with breast cancer. 
1.3.2 Biological mechanisms underlying poor outcome in overweight and obese breast 
cancer patients 
Several potential mechanisms have been proposed that could contribute to the adverse 
effects of obesity on risk of breast cancer in post-menopausal women (Rose & Vona-
Davis, 2009) as well as prognosis in pre- and post-menopausal women (Calle & Kaaks, 
2004; Vona-Davis & Rose, 2007) such as hormonal axes, metabolic pathways and host 
factors. 
Obese post-menopausal women have higher oestrogen levels due to excess 
aromatization of androgens to oestrogens in their peripheral adipose tissue. This results 
in increased cell proliferation in hormone sensitive breast cancer (Cleary & Grossmann, 
2009),  making oestrogen suppression a useful pharmacological tool for breast cancer 
therapy. Obesity, notably abdominal obesity, has been correlated with increased levels 
of circulating insulin, which has pro-angiogenic, pro-mitogenic and anti-apoptotic 
effects on breast cancer cells, contributing to a negative association with breast cancer 
prognosis (Goodwin et al., 2002). 
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Several studies have also appreciated the role of adipocyte-derived factors (adipokines) 
in the pathogenesis of obesity-related metabolic diseases, including insulin resistance, 
type 2 diabetes, cardiovascular disease (Blüher, 2009; Guilherme et al., 2008) as well 
as cancer progression due to hyperinsulinemia and angiogenesis that supports cancer 
cell growth, survival and metastasis  (Ameli et al., 2015). Low grade inflammation that 
accompanies obesity is characterized by release of pro-inflammatory cytokines (TNF-
α, IL-6) from activated macrophages that further exert a pro-tumorigenic influence on 
tumour microenvironment (Van Kruijsdijk et al., 2009). 
 Recent literature also highlights the role of “host factors” as one of the prime 
contributors to the occurrence of aggressive tumour characteristics such as advanced 
stage and high grade in obese breast cancer patients (Berclaz et al., 2004; Daling et al., 
2001; Daniell et al., 1993; Feigelson et al., 2006). Increased BMI adversely effects 
breast cancer prognosis due to a large proportion of more advance disease at diagnosis 
(Cui et al., 2002) requiring increased operation time and higher risk of surgical 
complications (Kaidar-Person et al., 2011), as well as sub-optimal chemotherapy 
treatment (Griggs et al., 2005) in this subset of patients. Long term adjuvant 
chemotherapy is linked with weight gain and/or change in body composition especially 
in premenopausal women (Vance et al., 2011). Prolonged periods of inactivity that 
occur during the treatment period cause altered energy balance, which could also 
contribute to weight gain (Makari-Judson et al., 2014). It has been shown that treatment 
with Aromatase inhibitors (AI) led to increased incidence of arthralgias in obese women 
as compared to their normal weight counterparts (Niravath, 2013) that caused non-
compliance to treatment of AI antibiotics adversely affecting breast cancer outcomes. 
1.4 The tumour microenvironment and local effects of stromal adipocytes. 
Emerging evidence has established the active role of the tumour microenvironment 
(TME) towards the progression of breast cancer (Jodele et al., 2006 ; Kessenbrock et 
al., 2010). Breast cancer is a tissue based disease and besides the role of epithelial cells 
and adipocytes, recent literature highlights a “tissue-integrated” view of tumour 
progression emphasizing the role of dynamic cross talk between epithelial cells and 
their surrounding tumour stroma (Mueller & Fusenig, 2004) (Figure 1.1). This stromal 
framework comprises cellular components such as fibroblasts, immune and 
inflammatory cells and blood vessels as well as the extracellular tumour matrix. 
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Naumav, Akslen & Folkman’s (2006) pioneering work recognized that tumours induce 
angiogenesis as a means to grow and metastasize to distant organs and hence targeting 
the tumour vasculature has become an important form of anticancer therapy (Naumov 
et al., 2006). However, emerging evidence suggests that besides endothelial cells, 
“cancer associated fibroblasts (CAFs)” or “tumour associated macrophages (TAMs)” 
also play an integral role in tumour progression by secreting pro-migratory extracellular 
matrix proteins, chemokines and growth factors (Bissell & LaBarge, 2005; Mueller & 
Fusenig, 2004). Two closely linked pathways have been suggested in the cross-talk 
linking cancer and stromal cells: (a) the “efferent” pathway, where cancerous cells 
initiate a reactive response in the stromal framework; and (b) the “afferent “pathway, 
in which activated stromal cells control cancer cell malignancy (De Wever & Mareel, 






Figure 1.1 Representative example of a “Tissue Integrated” overview of the breast tumour 
microenvironment showing different elements postulated to actively participate in breast cancer 
progression and invasion.  
Degradation of the basement membrane allows that tumour cells to communicate with resting resident 
fibroblast, thereby causing alteration in their phenotype towards CAFs. Invading cancer cells produce 
growth factors which stimulate angiogenesis and inflammation by the recruitment and activation of 
multiple different cells, including endothelial precursor cells, tumour-associated neutrophils and 
macrophages. Mature adipocytes (large yellow cells) surround the tumour and may undergo phenotypic 
change towards more fibroblast-like cancer associated adipocytes (CAA). (Sourced from Joyce & 




Is there a role for adipocytes in this “tissue integrated” view of tumour progression? 
Firstly, adipocytes are one of the most prominent cell types in breast tissue and share 
an intimate relationship with the mammary tissues. Secondly, it is also interesting to 
note that embryo breast buds develop in a bed of white adipose tissue. Thirdly, elaborate 
epithelial-mesenchymal interactions occur in a breast tumour microenvironment that 
culminate into adipose mesenchyme finally instructing the various aspect of mammary 
gland development (Wiseman & Werb, 2002). Finally, it is apparent that in breast 
tissue, early local tumour invasion occurs where cancer cells lie in close proximity with 
adipocytes (Bochet et al., 2011; Iyengar et al., 2005). Hence, it is logical to hypothesise 
that adipocytes play a pivotal role in the pathogenesis of breast cancer.  
1.4.1 Cancer Associated Adipocytes (CAA) 
An increasing body of evidence points towards stromal adipocytes having a profound 
effect on tumour progression. Adipocytes that were earlier thought to be simple energy 
storage depots have rather emerged as endocrine cells with an ability to secrete multiple 
heterogeneous group of molecules called adipokines (Iyengar et al., 2003; Nomura et 
al., 2010; Rajala & Scherer, 2003). During periods of excessive energy intake, the 
adipocytes initially undergo hypertrophy (increase in adipocyte size) and then 
hyperplasia (increase in adipocyte number) so as to accommodate increased energy 
requirements (Rosen & MacDougald, 2006; Spalding et al., 2008; Sun et al., 2011). In 
addition, they suffer physiological stresses such as hypoxia and oxidative stress that 
induce them to become dysfunctional with decreased metabolic flexibility (Spalding et 
al., 2008). This results in apoptosis and a resultant increase in the local accumulation 
of inflammatory cells (particularly macrophages) into the adipose tissue (Blüher, 2009; 
Qian & Pollard, 2010). These infiltrating macrophages surround the dying adipocyte 
and form ‘crown-like structures’ and release inflammatory mediators into the tumour 
microenvironment (Cinti et al., 2005). 
1.4.1.1 CAA in breast cancer 
In breast cancer, the tumour interface has an increased population of adipocytes, and 
these adipocytes are smaller in size than adipocytes situated in normal adipose tissue at 





Figure 1.2 Cancer-associated adipocytes (CAA) from human breast carcinoma exhibiting 
significant phenotypic changes along the interface. (A) Histologic examination of an invasive breast 
tumour after H&E staining (original magnification x200 Ad, adipose tissue; IF, invasive front); (B) 
Histologic magnification of the invasive front of the tumour. (Sourced from Dirat et al., American 
Association of Cancer Research, 2011).  
 
These small adipocytes appear delipidated with large interstitial spaces, displaying a 
decreased expression of late adipocyte differentiation markers and increased expression 
of inflammatory markers (Dirat et al., 2011). At the tumour centre, a high ratio of 
fibroblast-like cells to adipocyte cells is seen in the surrounding stroma. These 
observations have led to the notion that adipocyte-cancer cell heterotypic cross 
communication occurs along the interface of the tumour, leading to adipocyte 
dedifferentiation and increased generation and activation of fibroblast-like cells called 
Cancer-Associated Adipocytes (CAA) (Dirat et al., 2011; Dirat et al., 2010; Wang et 
al., 2012). These findings may also throw light on the origin of at least a sub-population 
of cancer-associated fibroblasts (CAFs), which could potentially originate from CAAs 





Figure 1.3. Histology of the invasive front and the centre of a human breast carcinoma.  
Haematoxylin-eosin histological examination. (A) The invasive front of a primary tumour. Features of 
connective tissues are dramatically modified in response to cancer cell local invasion. Most importantly, 
CAAs (lipids in white colour) located at the interface of invading cancer cells exhibit reduced size in 
comparison with normal adipocytes located at a distance; (B) The centre of the same tumour shows 
accumulation of fibroblasts/fibroblast-like cells (CAFs), and adipocytes are no longer present. (Sourced 
from Tan et al., International Journal of Developmental Biology, 2011). 
1.4.1.2 In vivo evidence that adipocytes favour tumour progression 
Recent studies have investigated the role of local adipose tissue invasion by tumour 
cells at the interface, with the data showing a correlation with adverse patient outcomes 
in breast cancers (Kimijima et al., 2000; Yamaguchi et al., 2008). 
Experimental data also report a similar impact of adipocytes on cancer progression. 
Scherer et al. (Iyengar et al., 2003) performed an in vivo murine study where they co-
injected breast cancer cell lines (SUM59PT) with murine adipocytes in immune 
deficient mice so as to recapitulate the heterotypic cross talk that would occur in 
primary breast cancer and demonstrated that adipocytes favour tumorigenesis. Using a 
similar model, Dirat et al. (2011) demonstrated that tail vein injection of breast cancer 
cells that were previously co-cultured with adipocytes cause increased lung metastasis 
than breast cancer cells grown alone (Dirat et al., 2011). 
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1.4.1.3 In vitro evidence that adipocytes favour cancer cell invasiveness 
Given that in vivo techniques might be limited by local and systemic factors, in vitro 
models have been developed by several laboratories to unveil the intrinsic functions of 
adipocytes in a breast cancer tumour microenvironment. One of the earlier models used 
mature adipocytes in a three dimensional (3D) collagen gel matrix cultures, and 
observed that the growth of breast cancer cell lines increased via cancer-stromal cell 
interactions (Manabe et al., 2003). Similarly, in a 3D collagen gel matrix co-culture 
experiment, mature adipocytes secreted a factor(s) that enhanced the growth of breast 
cancer cell lines as demonstrated by the enhanced uptake of bromodeoxyuridine 
(Manabe et al., 2003). 
More recently as shown in Fig1.4, Dirat et al. developed a unique transwell co-culture 
system using mature adipocytes and breast cancer cell lines that were physically 
separated by a permeable membrane which allowed the passage of soluble factors 
between compartments, so as to investigate whether the exchange of these factors 
effected the two cell types. Subsequently, it was observed that both adipocytes as well 
as breast cancer cells underwent changes in their phenotype following co-culture. 
Adipocytes that were co-cultured with breast cancer cells showed a change in 
morphology by acquiring a more elongated, tapering phenotype along with delipidation 




Figure 1.4. Schematic representation of the in vitro transwell co-culture model showing adipocyte-
cancer cell crosstalk leading to adipocyte de-differentiation.  
(A) Schemes showing the transwell co-culture model allowing the passage of soluble factors yet 
providing a physical barrier for cell-cell contact. (B) Adipocytes co-cultured in the presence of breast 
cancer cells (AdBCC) show delipidation and more elongated fibroblast like phenotype as compared to 
adipocytes cultured alone (Ad). (Sourced from Tan et al., International Journal of Developmental 
Biology 2011). 
 
These observations were in line with the in vivo observations that were made by the 
earlier studies along the invasive front of the breast cancers (Andarawewa et al., 2005; 
Dirat et al., 2011). Although, no change in the morphology of cancer cells was 
observed, they showed a difference in their biological behaviour by becoming more 
migratory and invasive and resistant to chemotherapy agents, as compared to the cells 
that were not cultured with adipocytes (Dirat et al., 2011). 
Similar experiments were conducted (Bochet et al., 2011) to delineate the role of 
tumour-surrounding adipocytes in imparting a radio-resistant phenotype to breast 
cancer cells.. They demonstrated that breast tumour cells co-cultivated with mature 
adipocytes exhibited radio-resistance. It was also observed that increased expression of 
Chk1 was associated with decreased cell death as compared to tumour cells that were 
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grown alone. In addition, it was also noted that adipocyte-induced tumour changes 
taking place during the co-culture period preceding the exposure to ionising radiation 
(IR) were enough to impart the radio-resistant phenotype (Bochet et al., 2011). 
1.4.2 Collagen secreted by CAA may promote breast cancer cell metastasis 
The tumour microenvironment comprises cellular (e.g. adipocytes, fibroblast, 
endothelial and immune cells) as well as non-cellular elements (e.g. proteins, proteases, 
cytokines and the extracellular matrix). Recent literature has revealed the importance 
of the structure and composition of the extracellular matrix in various cellular processes 
such as cancer cell proliferation, differentiation and metastasis (Discher et al., 2005; 
Georges & Janmey, 2005). It has been shown that extracellular matrix structure plays 
an important role via its effects upon cell morphology, integrin signaling and regulation 
of cell cycle (Assoian & Klein, 2008; Chun et al., 2006; Paszek et al., 2005).  
Recent research in our own laboratory (Dr Elisabeth Phillips, Mackenzie Cancer 
Research Group, UOC) used a global discovery approach and Mass Spectrometry to 
identify over 300 proteins in the secretome of CAA following 3 days of transwell co-
culture with oestrogen receptor positive (MCF7) and hormone receptor negative 
(MDA-MB-231) human breast cancer cells. This study revealed that CAA secreted 
large amounts of collagen, particularly collagen I, when exposed to breast cancer cells 
in transwell co-culture (pers. comm. Dr Elisabeth Phillips), suggesting that CAA may 
be an important source of collagen in the tumour microenvironment. 
Previous studies have reported that CAA secrete extracellular matrix proteins 
(including collagen VI) that contribute to breast cancer progression (Andarawewa et 
al., 2005; Iyengar et al., 2005; Park & Scherer, 2012). In addition, recent studies have 
revealed that collagen I is capable of acting as a ligand to stimulate cell-signaling 
pathways involved in cancer cell EMT (Valiathan et al., 2012). 
1.5 The role of collagen in breast cancer cell metastasis 
Metastasis is a lethal milestone in cancer and is characterized by intravasation, invasion 
and extravasation. To further quantify the lethality, it has been estimated that less than 
1% of cancers undergo this phenomenon, but metastasis contributes to over 90% of 
deaths due to cancer (Sleeman & Steeg, 2010; Steeg & Theodorescu, 2008). During 
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metastasis, tumour cells acquire genetic and epigenetic alterations as well as respond to 
external biophysical and micro environmental influences (Fang et al., 2014; Gelain et 
al., 2006). 
Invasion and intravasation are the early stages of metastasis that allow metastatic cells 
to move from the tumour into the ECM, breaking through the basement membrane to 
enter into the blood vessels. The exact mechanisms underlying intravasation are not 
fully understood, but pathological studies have suggested that metastatic cancer cells 
have a highly branched phenotype and distinctly utilize the aligned extracellular matrix 
(ECM) during metastatic cancer progression (Gelain et al., 2006; Xu et al., 2001). 
Logically, one would assume that the critical step here would be for the cancer cells to 
travel through the endothelial layer of the blood vessels to access the blood stream. 
However, recent literature shows that intra tumoural intravasation may not necessarily 
be preceded by local invasion and could either be preceded by, in parallel to, or 
independent of, tumour cell invasion into the surrounding matrix (Deryugina & 
Kiosses, 2017). Irrespective of the method of intravasation, it has been a difficult 
phenomenon to visualize and mimic in scientific models, and researchers have come to 
believe that it is a rare phenomenon. This is in sharp contrast to studies that have 
reported that about 1 million cancerous cells per 1gm of tumour tissue is able to disperse 
via the circulation daily (Chang et al., 2000). However, successful studies have shown 
that cancer cells move singly or in clusters during intravasation (Gilkes et al., 2013; 
Khoja et al., 2012; Martin & Boyd, 2008; Riching et al., 2014; Yu et al., 2013). 
The breast tumour microenvironment is unique in that it is marked by the presence of 
dense collagen rich stroma, also known as “desmoplastic response”, characterized by 
increased deposition of Type 1 and Type III collagens and a degradation of Type IV 
collagen (Huijbers et al., 2010). Collagen I is the most predominant ECM protein with 
multiple pro-tumourigenic effects (Levental et al., 2009; Provenzano et al., 2006; 
Provenzano et al., 2008). Generally, collagen deposition relies upon the presence of 
matrices that have been preassembled under the action of another ECM glycoprotein, 
Fibronectin (McDonald et al., 1982; Sottile & Hocking, 2002; Velling et al., 2002). 
These Fibronectin induced matrices have increased stiffness and viscosity that promote 
pro-angiogenic signalling pathways (Wang et al., 2015). Also, Wang et al. (2016) 
highlighted the role of CAFs and observed that these cells initially assembled a strained 
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matrix that was further remodelled into a thick collagen I rich matrix under the 
influence of matrix metalloproteases (MMPs). 
1.5.1 Collagen in the breast tumour extracellular matrix (ECM) 
In the breast tumour microenvironment, it has been reported that cancer cells intravasate 
by traversing along reorganized interstitial collagen fibrils prior to traversing through 
the endothelium to access the blood vessels and lymphatic capillaries (Cil et al., 2009; 
Dang et al., 2011). Provenzano et al. (2006) first studied epithelial-stromal interactions 
in mouse mammary tissues using histology, electron microscopy, laser-scanning 
multiphoton (MPLSM) and second harmonic generation (SHG) microscopy from 
unstained sections obtained from mouse mammary tumours. (Provenzano et al., 2006). 
They put forth three Tumour-Associated Collagen Signatures (TACS) as newer 
markers to further locate and characterize these tumours (see Fig 1.5). TACS-1 is 
defined as a localized increase in relaxed wavy collagen fibrils. TACS-2 is defined as 
tangential appearance of collagen fibres aligned parallel to the tumour boundary. 
TACS-3 refers to the orientation of collagen fibres oriented at steep angles sometimes 
radially aligned to the tumour boundary. It has been postulated that tumour cells may 
travel along the straightened, perpendicularly aligned TACS-3 collagen fibres as ‘high 
ways’ for invasion and metastasis. (see Fig 1.6) Hence TACS have been used to stage 
the progression levels of breast carcinoma (Bredfeldt et al., 2014; Conklin et al., 2011; 




Figure 1.5. Tumour-Associated Collagen Signatures (TACS).  
Multiphoton image of an isolated ex vivo mouse breast tumour (MMTV-PyVT) containing distinct 
collagen organizational phenotypes using Second Harmonic Generation (SHG) signalling. This image 
contains all three of the archetypal TACS: TACS-1 retains a relaxed wavy appearance and is found 
throughout the tumour (green arrow). TACS-2 refers to the straightened appearance of individual 
collagen fibres (orange arrows), and TACS-3 is defined as straightened collagen fibres oriented radially 
away from the tumour boundary (yellow arrows). Scale bars 50. (Sourced from Provenzano, et al., 2006., 




Figure 1.6 Tumour cell invasion along TACS-3 aligned Collagen fibrils.  
(A) Illustration showing metastatic tumour cells using collagen fibrils as ‘highways’ to invade towards 
the basement membrane and blood vessels during the process of invasion and metastasis. (B) H&E 
stained slide of human breast carcinoma showing disseminating cancer cells migrating along TACS-3 
(arrows) collagen fibrils towards a nearby blood vessel. (C) SHG (Second Harmonic Generation) image 
of the same tumour location reveals the underlying collagen matrix (Fig 6A sourced from Han et al., 




The Keely laboratory and others also studied mice using multiphoton spectral lifetime 
imaging microscopy (SLIM) using an advanced system that was derived from the 
previously described model (Provenzano et al., 2006; Schedin & Keely, 2011; Arendt 
et al., 2010 ; Boyd et al., 2011; Levental et al., 2009)). Conklin et al. (2011) provided 
the first bridging study between mouse models and human diagnostic pathology by 
using Tissue microarrays (TMA) from breast cancer patients (Conklin et al., 2011). 
They qualitatively searched for these TACS patterns by extensive manual analysis. 
They found that the presence of TACS-3 was an independent prognostic marker for 
both disease-specific and disease-free survival for patients with invasive breast cancer, 
as was progesterone receptor, ER, node status, and tumour size (Conklin et al., 2011). 
However, the common limitation with these studies was the cost, poor accessibility and 
time required for the analysis. To the best of my knowledge, these processes have not 
been utilized in clinical practice. 
Recent studies have developed in vitro 3D cell culture models to further investigate the 
cellular and mechanical processes underlying the local collagen fibre reorganisation 
and alignment. 3D models developed to study linear oriented matrices in micro-
channels by mechanical strain have highlighted that 3D matrix alignment supports 
consistent migration of tumour cells (Martin & Boyd, 2008 ; Provenzano et al., 2006; 
Conklin, 2011; Carey, 2013; Vader, 2009). For example, Valencia et al. (2015) used 
spheroids as an early tumour model for the process of intravasation and used these to 
investigate cell behaviour within and around them. They observed that these cells 
aligned at right angles to the spheroid surface as a result of the traction forces from the 
cells within the spheroid that led to reorganisation of the collagen matrix (Valencia et 
al., 2015). Another study observed that both epithelial cells and fibroblasts utilised the 
associated ECM proteins to prompt the Rho- and Rho kinase (Rock) pathway to activate 
actin myosin contractility and allow the alignment of collagen fibres (Conklin et al., 
2011; Goetz et al., 2011; Provenzano et al., 2006).  
A basic in vitro 3D ECM model to represent breast cancer cell metastasis should include 
structures representing both interstitial matrix and basement membrane with several 
degrees of heterogeneities (for example, locally oriented collagen fibres). In an attempt 
to mimic this composite tumour microenvironment, Han et al. established an 
engineered tumour microenvironment within a microfabricated chip matrigel model, 
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positing the aforementioned archetype/prototype. Specifically, they found that 
metastatic MDA-MB-231 breast cancer cells utilised the locally aligned collagen fibre 
for the process of intravasation into rigid matrigel (Han et al., 2016). 
Tumour ECM stiffening is associated with a higher degree of covalent cross linking 
among collagen molecules (Levental et al., 2009). CAF also express lysyl hydroxylase 
(LOX) during the early steps of breast carcinogenesis that catalyzes collagen cross-
linking, whereas in the later stages LOX is produced in hypoxic cancer cells and 
promotes aggressive tumour growth (Santhanam et al., 2010). Hence, LOX activity 
promotes ECM remodelling that further facilitates tumour cell migration and invasion. 
It is interesting to note that in a murine model it has been observed that treatment with 
LOX inhibitors led to impeded cross linking that subsequently prevented ECM 
stiffening and tumour progression (Levental et al., 2009). Another recent study by 
Grossman et al. monitored different stages of collagen fibrillary alignment using 
advanced microscopic tools in a native fibroblast 3D matrix system. They observed that 
anti-lysly oxidase-like 2 (LOXL2) antibodies disrupted the natural alignment of 
endogenous fibrillary collagens without interfering with the ECM composition, which 
negatively affected the adhesion and migration of the human breast carcinoma cells 
(Grossman et al., 2016). Therefore, it is possible that this novel strategy could be used 
to disrupt the tumorigenic collagen supra structure, and thereby utilise it as a therapeutic 
approach to treat ECM related pathologies. 
It has been shown that radiotherapy promotes the specific alignment of collagen 1 
matrices to some extent (Chon & Loeffler, 2002; Lin et al., 2008; Pandya et al., 2014; 
Théry et al., 2006). If there are cancer cells in the microenvironment that have survived 
the effects of radiotherapy, the aligned collagen fibres might provide them with 
‘highways’ for invasion and metastasis. Hence, it can be proposed that future therapies 
could potentially be targeted towards tuning the tumour microenvironment, wherein the 
patients could receive a ‘tissue therapy’ that would misalign and recover the collagen 
fibres to their un-oriented state, thereby minimising the intravasation potential of the 
metastatic cancers. Although the literature describes some of these strategies that would 
potentially inhibit fibre formation and or assembly, including physical (Baumketner, 
2014; Li et al., 2013; Stone et al., 2003) and chemical (Li et al., 2012; Soto et al., 1998) 
approaches, a detailed description of these therapies is beyond the scope of this review. 
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1.5.2 Collagen acting as a ligand for Discoidin Domain Receptors 
Emerging evidence describes another possible mechanism whereby collagen may exert 
its pro-malignant effects in the breast tumour microenvironment, and that is by acting 
as a ligand mediating the action of specific collagen receptors called Discoidin Domain 
Receptor 1 (DDR1) and DDR2. These receptors are highly homologous, and upon 
binding to collagen undergo auto-phosphorylation leading to the activation of a cascade 
of intracellular signalling events (Valiathan et al., 2012). DDR1 is activated by both 
fibrillary (mostly type I and V) as well as non-fibrillary (type IV) collagen, whereas 
DDR2 is unique as it is entirely activated by fibrillar collagen (Valiathan et al., 2012). 
In normal tissues, DDR1 expression is limited to epithelial cells and DDR2 is only 
expressed in mesenchymally transformed stromal cells, where it controls ECM 
synthesis and takes part in wound healing (Alves et al., 1995; Valiathan et al., 2012). 
More recently, Maeyama et al., (2008) have observed a striking increase in DDR2 
expression levels and a corresponding decrease in DDR1 expression levels in 
mesenchymal cells (Maeyama et al., 2008). In breast cancer cells, DDR2 has been 
reported to stabilise Snail1 activity and thereby facilitating epithelial-to-mesenchymal 





 Figure 1.7. Discoidin Domain Receptor (DDR) 2 are activated by fibrillary type 1 collagen and 
promote the process of EMT in cancer cells. (Sourced from Gonzalez et al., 2017, Cell Reports).  
 
 Pathological over expression of DDR2  has been observed in many human 
malignancies, including breast cancer, where it has been significantly correlated with 
worse survival (Badiola et al., 2011) (Barcellos-Hoff et al., 2013; Kim et al., 2015; Ren 
et al., 2013; Toy et al., 2015).  
Tumour metastasis is a multistep process, with EMT believed to be an initial and critical 
step that allows a functional transition of polarized epithelial cells into spindle shaped 
mobile cells with increased invasiveness and resistance to apoptosis (Kalluri & 
Weinberg, 2009; Thiery, 2002; Wang & Shang, 2013; Zeisberg & Neilson, 2009). 
Interestingly, epithelial cells are known for their plasticity and ability to switch back 
and forth between an epithelial and mesenchymal phenotype via the pheneomenon of 
EMT and mesenchymal-epithelial transition (MET), respectively (Gumbiner, 1992; 
Kalluri & Neilson, 2003). Hence, EMT generates migratory mesenchymal cancer cells 
that intravasate into the circulation, then extravasate and settle into secondary nodules 
exhibiting an epithelial phenotype via the process of MET (Kalluri & Neilson, 2003). 
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However, there remains some argument whether the transformation of a non-invasive 
tumour cell into an invasive tumour cell is truly due to EMT (Tarin, 2005). The role of 
EMT in cancer appears from the rarity of the EMT-like morphological changes that are 
observed in primary tumour and also from the observation that metastases appear 
histologically similar to the primary tumour (Kalluri, 2009).  
Although Fraser, Nieto and colleagues have discussed the signalling pathways involved 
in EMT (Acloque et al., 2009; Kalluri & Weinberg, 2009), it remains uncertain what 
specific mechanisms cause EMT in epithelial cells. Several experiments performed in 
cell culture and mouse models have detected changes in the phenotype of epithelial 
cells undergoing EMT as they become fibroblastic (Greenburg & Hay, 1982). Recent 
human studies have also begun to unfold the phenomenon of EMT in organ fibrosis and 
tumour metastasis (Bataille et al., 2008; Brabletz et al., 2001; Rastaldi et al., 2002; 
Reckamp et al., 2008; Trimboli et al., 2008), but these studies are still in their infancy. 
Common molecular markers that characterise the phenomenon of EMT include 
increased expression of N-cadherin and vimentin, nuclear localization of β-catenin, and 
increased production of the transcription factors such as Snail1 (Snail), Snail2 (Slug), 
Twist, EF1/ZEB1, SIP1/ZEB2, and/or E47 that inhibit E-cadherin production.   
Although a majority of metastases are eradicated by the immune system before lodging 
at a distant focus in the body, those which survive need time to evolve from individual 
cells into observable tumours (Hanahan & Weinberg, 2011). Consequently, cancer 
patients can have unobserved micrometastases at the time of surgery of their primary 
tumour. Measuring the expression levels of EMT markers in the primary tumours may 
point towards the tumour’s metastatic potential. This may aid the clinicians to optimise 
best treatment modalities for their patients. More specifically measurement of EMT 
markers expression levels could be crucial to assess risk stratification and possibly 




1.6 Thesis Outline  
Previous studies have shown tumour-associated collagen can promote breast cancer cell 
metastasis by altering the stromal matrix or by activating signalling pathways that lead 
to carcinoma cells undergoing EMT. Recent, unpublished work in our own laboratory 
has revealed that cancer-associated adipocytes (CAA) secrete large amounts of collagen 
(particularly collagen I). Therefore, the working hypothesis for this study was that 
collagen secreted by CAA modifies the tumour microenvironment and/or tumour cell 
phenotype to promote breast cancer cell invasion and metastasis. 
To investigate this, I performed trichrome staining and immunohistochemical analysis 
on formalin fixed paraffin embedded (FFPE) tumour samples from n=46 post-
menopausal (aged 51yr+) women with invasive breast carcinoma. This cohort included 
women with TNBC and oestrogen receptor (ER) positive breast cancer, who were 
normal weight (Body Mass Index=20-24.9) or obese (BMI>30). 
In Chapter 2, I used Haematoxylin & Eosin (H&E) staining, Trichrome staining and 
collagen 1 immunostaining to determine the number and size of CAA in each tumour, 
as well as the pattern of collagen deposition, and analysed these together with patient 
clinicopathological data. 
Hypothesis 1: A high number of CAA at the tumour interface and/or within the tumour 
stroma is associated with increased collagen deposition around the CAA and within the 
breast tumour microenvironment, and poor patient outcome (Chapter 2). 
In Chapter 3, I performed additional immunohistochemical analysis using anti-DDR2, 
anti-vimentin and anti-Snail 1 antibodies to investigate whether collagen was acting as 
a ligand to stimulate Discoidin Domain Receptor 2 (DDR2) and promote breast cancer 
cell metastasis. 
Hypothesis 2: A high number of CAA at the tumour interface and/or within the tumour 
stroma is associated with increased levels of DDR2 protein, markers of breast cancer 




Chapter 2  
The role of CAA and extracellular collagen in 
breast cancer cell invasion and metastasis 
2.1 Introduction 
Breast cancer is the commonest cancer for New Zealand women and the third most 
common cancer overall. Eight New Zealand women, on average, hear the news each 
day that they have breast cancer, and >600 women die of the disease every year. These 
figures also reflect risk assessment in other Western nations such as UK and USA 
(IARC and WHO, 2017). 
Diagnosis and treatment of breast cancer has progressed remarkably due to the advent 
of several molecular techniques based on immunohistochemistry (IHC) (Elledge & 
Allred, 1998), fluorescence in situ hybridisation (FISH) (Press M, 2002) and reverse 
transcription polymerase chain reaction (RT-PCR) (Habel LA, 2006). However, there 
still remains a need to discover new diagnostic, prognostic and predictive biomarkers, 
particularly those that are readily analysed, because these can potentially enhance 
pathological assessment and help predict patient outcome. One promising area of 
development is image-based assays for predicting patient outcome utilising the standard 
histopathological sections prepared as a part of the normal clinical workflow and 
supplemented with specialised stains.  
On a mammogram, fat appears translucent or dark, whereas stromal and epithelial tissue 
appears radiopaque or white. High mammographic density has been associated with 
increased collagen-rich stroma, more glandular tissue and decreased fat content (Britt 
et al., 2014). Research indicates (Boyd et al., 2002) that women with 
mammographically dense breasts have a 2- to 6-fold increase in their susceptibility to 
develop breast cancer, and similar relative risk values were also reported by Britt et al. 
(2014). Previous studies have observed links between increased collagen deposition, 
changes in collagen deposition patterns and poor breast cancer patient outcome 
(Conklin et al., 2011). 
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Provenzano et al. (2006) first introduced the Tumour Associated Collagen Signature 
(TACS) nomenclature to describe collagen alignment patterns. The TACS phenotypes 
are currently classified into three groups. TACS-1 describes the standard desmoplastic 
response of increased collagen deposition surrounding initiating tumour cells, and 
appears as relaxed, curving fibrils. TACS-2 is observed as straightened fibres aligned 
tangentially around developing tumours, while TACS-3 is seen as radially aligned 
fibres that facilitate local invasion (Provenzano et al., 2008). Conklin et al. qualitatively 
searched for these patterns in human breast cancer samples, and through extensive 
manual analysis found that the presence of the TACS-3 alignment phenotype was a 
prognostic indicator for disease free and disease specific survival (DFS and DSS, 
respectively) for invasive breast cancer patients (Conklin et al., 2011). 
Previous collagen alignment studies have been further facilitated by the development 
of modern methods like second harmonic generation signalling (SHG), fluorescence 
lifetime imaging microscopy (FLIM) and multiphoton microscopy (MFM), but these 
techniques are currently impractical in clinical practice due to the limitations of cost 
and accessibility. Moreover, one key feature that is missing from all the available image 
analysis techniques is the ability to incorporate cellular information into the analysis. 
Therefore, the challenge that still remains is to translate this correlation into a routine 
pathology workflow. In considering less expensive substitutes, the options include 
selective demonstration of collagen fibres by specialised stains like Masson’s trichrome 
and Sirius red. Since Masson’s trichrome is the gold standard stain for collagen and is 
used by the Anatomical Pathology Department at the Christchurch DHB, it was the 
preferred method for the current study. 
Cancer metastasis is a complex multistep phenomenon influenced by reciprocal cross 
communication between epithelial and stromal components (Joyce & Pollard, 2009; 
Mueller & Fusenig, 2004). On one hand, epithelial cells exhibit a pro-tumorigenic 
microenvironment by activating host wound response (Schäfer & Werner, 2008). On 
the other hand, stromal cells such as CAA secrete growth factors, chemokines and ECM 
proteins like collagens that provide physical support to the cancer cells for invasion and 
migration (Joyce & Pollard, 2009). Given that breast tumour microenvironment has a 
significant stromal adipocyte content, obesity-related paracrine alterations in breast 
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adipocytes cause further tumour promoting influence on breast cancer (Rose & Vona- 
Davis, 2009). 
Some previous studies have shown markedly elevated levels of adipocyte derived 
collagen VI in obese individuals, which is associated with tissue fibrosis, metabolic 
dysfunction and insulin resistance (Khan et al., 2009). This may have implications, 
especially in the context of breast cancer patients, as fibrosis is an epidemiologically 
well-established risk factor for this cancer (Boyd et al., 2005). Despite the abundance 
of epidemiological evidence, the precise biological mechanisms leading to fibrosis and 
the contribution of different collagen subtypes towards this are not well understood and 
require further exploration. 
Studies in our laboratory at the Mackenzie Cancer Research Group, have shown that 
when mature human breast adipocytes are co-cultured with oestrogen receptor positive 
(MCF7) and hormone receptor negative (MDA-MB-231) human breast cancer cell lines 
they alter phenotype to become smaller and more fibroblast-like, resembling cancer-
associated adipocytes (CAAs), and release large amounts of collagen - particularly 
collagen I (personal communication, Dr Elisabeth Phillips). However, further single 
cell microscopic and molecular evaluation of breast tumour samples for CAA, cancer 
cells and collagen I alignment patterns was not performed, and this provided the 
rationale for the current study. 
To summarise, although there is overwhelming epidemiological evidence supporting a 
breast cancer/obesity connection (Chan & Norat, 2015), the underlying mechanistic 
basis linking obesity per se to tumour initiation and progression are limited. 
Furthermore, few studies have explored associations between CAA, collagen alignment 
patterns (TACS types) and breast cancer patients clinicopathological parameters 
(obesity, menopausal status, stage, grade, LVI, tumour subtypes), or investigated 
whether there are any correlations between these parameters and poor patient outcome, 
and this further laid the foundation for the current study. 
The study in this Chapter arose from the following research questions: 
1. Do CAA produce collagen in breast tumours (particularly collagen I)? 
2. If so, is the collagen produced by CAA altering the ECM in such a 
way as to facilitate breast cancer metastasis? 
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3. Is TACS-3 more common in breast tumour tissue with a greater 
number of CAA present? 
 Hence, the current study was undertaken with the following hypotheses: 
1. Collagen (particularly collagen I) is deposited more densely around CAA. 
2. Tumour Associated Collagen Signature-3 (TACS-3) is more common in breast tumour 
tissue with a greater numbers of CAA present. 
Objectives: 
This study aimed to investigate tumour stromal interactions at single cell level using 
microscopic histopathological techniques with specialised trichrome stain and collagen 
I immunohistochemistry with the following objectives: 
1. To measure Cancer Associated Adipocyte (CAA) number, size and area at the tumour 
interface and within the tumour. 
2. To determine the pattern of collagen deposition at microscopic level using specialised 
Trichrome stain. 
3. To determine the levels and location of collagen I protein using immunohistochemistry. 





2.2 Methods and materials 
2.2.1 Study design and case selection 
In this study, our cohort comprised of a group of 60 post-menopausal breast cancer 
patients whose archived breast tumour specimen tissue blocks were stored with the 
Cancer Society Tissue Bank Christchurch (CSTBC). The patients underwent surgery at 
Christchurch Hospital, New Zealand, 2003-2012. In all cases ipsilateral axillary lymph 
node dissection was performed. The specimens had been dissected and histologically 
reported by specialist pathologists (Anatomical Pathology (CDHB) according to Royal 
College of Australasia (RCPA) guidelines. Several discrete histological parameters 
including lymphatic invasion, venous invasion and lymph node metastasis were 
additionally examined. 
After approval from the institutional review board, archived samples were screened for 
suitability of study. This study aimed to obtain n=15 breast tumour samples for each of 
four post-menopausal (≥51 years) breast cancer patient groups: (1) Oestrogen receptor 
positive (ER+), normal weight (Body Mass Index = 20-24.9; patients with BMI<20 
were excluded), (2) ER+, obese (BMI≥30), (3) hormone receptor negative/TNBC, 
BMI=20-24.9, and (4) TNBC, BMI≥30. There remained 46 cases in the study after low 
quality paraffin blocks were excluded. In addition, some stained samples were not of 
suitable quality to analyse due to sectioning artefacts and damage. 
Clinicopathological data was obtained from the CSTBC and Anatomical Pathology 
Department, CDHB, and the clinicopathological features from the 46 cases of invasive 
breast carcinoma used in this study are summarised in Table 2.1. The samples were 
retrospectively characterised with respect to histological subtypes such as invasive 
ductal, lobular, mucinous and mixed types. The histological grade was determined after 
the Nottingham Prognostic Index (NPI). The tumours were further characterised by 
tumour size, tumour grade, lymph node status, stage, and ER/PR/HER2 status. 
2.2.2 Ethics Statement 
The study was approved by the University of Otago Human Ethics Committee 
(Approval number 12/319), and all the patients gave informed written consent for future 
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unspecified use of tissue and clinicopathological data for research at the time of pre-
administration appointment prior to surgery. 
2.2.3 Histopathological staining techniques 
Serial formalin fixed paraffin embedded sections were cut (4µm) and mounted on glass 
slides for each breast tumour sample by the CSTBC. The order of section staining was 
kept the same for each tumour sample: (1) Haematoxylin & Eosin (H&E), (2) Masson’s 
Trichrome, (3) collagen I, (4) DDR1, (5) DDR2, (6) vimentin, and (7) Snail1. The 
collagen stains (Masson’s and collagen I) are described in Chapter 2, and the markers 
of EMT (DDR2, vimentin and Snail1) are described in Chapter 3. 
 2.2.3.1 Masson’s Trichrome stain 
Sections were dewaxed to water, washed in running water until sections were clear and 
then rinsed in distilled water. The first stain applied was Krutsay’s haematoxylin for 10 
minutes at room temperature. The sections were then washed in water and dipped in 
Scott’s tap water for 5 minutes to achieve blueing. The slides were then washed with 
water and stained with Scarlet-acid fuchsin for 15 minutes. Further to this, 
differentiation was achieved by placing the slides into phosphomolybdic-
phosphotungstic acid for 15 minutes. After rinsing in water, the sections were 
counterstained with Aniline blue for 6 minutes. The sections were then washed again 
with water, and final differentiation was achieved by staining with 1% acetic acid for 3 
minutes. Finally, the sections were rinsed in water, dehydrated through an ascending 
alcohol series and xylene, and mounted using DPX (distyrene, plasticizer and xylene). 
To assess collagen organisation from breast cancer patients, H&E stained samples were 
first analysed under low magnification (5x) for an overview. A wide range of 
histopathological features were observed such as varying adipocyte size, stromal 
fibroblasts, immune cells and cancer cells along with collagen fibril rich stroma. Further 
examination of the sections under higher magnification (10x) revealed a broad array of 
architectures between epithelial cell clusters and extracellular matrix. Some areas 
showed well-defined borders around epithelial cell nests, while others displayed poor 
tumour margins with extracellular matrix intercalated between individual cancer cells. 
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The relative concentration of collagen and the orientation of fibrils with respect to 
epithelial cells were further assessed with Masson’s Trichrome staining. Samples that 
exhibited a localised increase in the deposition of relaxed wavy collagen fibrils near the 
tumour lesion were given a score of TACS-1. Parallel alignment and straightening of 
collagen bundles relative to tumour nests was noted and sections with these features 
were scored TACS-2. Focal areas of invasion were carefully observed and sections 
where the collagen bundles were aligned at steep angles to individual tumour cells were 
scored as TACS-3. 
2.2.3.2 Collagen 1 
Immunohistochemistry 
Immunohistochemical staining for collagen I was performed manually using Cell and 
Tissue Staining Kits HRP-DAB Systems (R&D Systems, Minneapolis, MN, USA) 
following the manufacturer’s protocols. In brief, sections (4μm) were deparaffinized, 
rehydrated and endogenous peroxidases blocked using 1% H2O2 for 15 mins. For 
antigen retrieval, slides were incubated (95°C, 40 min) in citrate buffer. Sections were 
incubated with primary anti-collagen I antibody (Abcam MAb 2538; 1:800 dilution) 
and biotinylated secondary antibodies (rabbit/ mouse link, Dako Envision), then 
counterstained and mounted using an automated unit (Leica CV 500). The specificity 
of observed tissue staining was confirmed using omission of primary antibody, and 
liver sections containing metastatic colorectal carcinoma with fibrosis were used as 
positive controls. 
Quantification of immunohistochemical staining 
Immunohistochemistry was evaluated by the candidate (MP) blinded to 
clinicopathological data, and evaluation was checked by consultation with  Anatomical 
Pathologist, Dr Andrew Miller, Canterbury DHB, Christchurch. 
2.2.3.3 Image analysis 
Selection of regions of interest (ROI) 
All slides were evaluated with Axio Imager Z1 bright field microscope (Carl Zeiss, 
Germany) with sections first viewed under 5x objective to locate regions of interest 
(ROI) (Fig 2.3). ROI were defined as independent selected areas along the invasive 
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front (IF; n=3) and within the tumour proper (Tm; n=3). Each area was at least 50% 
covered by tumour lesion. The ROI within the tumour were in areas with highest stage 
as characterised by Nottingham Prognostic Index (NPI), and each ROI was without 
artefacts, areas of necrosis and uneven immunostaining. ROI were visualised under 20x 
magnification to obtain a clear evaluation of both epithelial and mesenchymal cells in 
terms of cell type, localisation of protein (cytoplasmic or nuclear), intensity and pattern 
of staining. These regions were then further analysed under higher magnifications (40x, 
64x oil) and images saved with a linear scale bar. 
Image Analysis by Image J software 
Images were saved with coded patient ID to maintain patient confidentiality and ensure 
blinding to patient clinicopathological information during analysis. The images were 
analysed using the free open access software ImageJ (LOCI, University of Wisconsin-
Madison). The first step was to calibrate the image. This process allows the programme 
to recognize the size of the sample based on the number of pixels and the magnification 
of the microscope (pixel aspect ratio=1, unit of length=µm, unit of area=µm2). Once 
the calibration settings were known, they were used for all subsequent images taken at 
the same magnification. 
2.2.4 Statistical Analysis 
Statistical analysis included all available clinical and tumour pathology parameters and 
was performed by SPSS® for Windows version 17 (SPSS Inc., Chicago, IL, USA). 
Descriptive statistics were presented as mean ± SD or frequency counts. Categorical 
variables were compared by the Chi-square or Fisher’s exact test. Non-parametric tests 
used were Wilcoxon Signed Ranks test and Kruskal-Wallis test with Dunn’s post-test. 
Correlations between continuous variables were analysed using Spearman’s rank 
correlations. Cox Regression analysis was used to analyse follow-up data (death, 
metastasis). Survival distributions were analyzed using Kaplan-Meier plots and 
compared by the log rank test. All tests were two-sided, and p-values<0.05 was 
considered significant. Statistical analysis was performed by Prof. Chris Frampton 





2.3.1 Clinicopathological features of the study cohort 
The clinicopathological features of the patients and tumours studied are presented in 
Table 2.1. All patients were female, with an average age at surgery of 63.5 years 
(range=51-84 yrs). Twenty-three patients had ER+ tumours (n=11 with BMI=20-24.9, 
n=12 patients with BMI>30). Twenty-three patients had triple negative breast cancer 
(TNBC; ER-, PR-, HER2-) (n=10 with BMI=20-24.9, n=13 with BMI>30). In the 
normal weight category, patients with BMI<20 were excluded from the study. The 
majority of patients were NZ European (87%) and had Ductal Carcinoma No Special 
Type (76%). 
 
2.3.2 Masson’s Trichrome staining optimization 
In search of a selective staining agent to provide the best visualisation of stromal pan-
collagen deposition in human breast carcinoma, Masson’s trichrome stain was used 
with Bouins solution as the fixative. Optimisation of the tricoloured staining technique 
was challenging, as after achieving good nuclear differentiation with Gill’s 
Haematoxylin in the first step, nuclear details were lost with application of the 
subsequent two stains (scarlet red and aniline blue), which could lead to 
misinterpretation of histopathological observations. Hence, different types of 
haematoxylin solutions were tested including Abcam, Gill’s and Krutsay’s (iron) 
haematoxylin, respectively (Fig 2.1A, B and C). The best results were obtained with 
Krutsay’s haematoxylin (Figure 2.1C and Fig 2.2), and so this was used in all 
subsequent Masson’s trichrome staining. This study highlighted that the key element 
of this staining technique was the addition of fresh alum-iron mordant to the 
haematoxylin dye just before immersion in order to bind and provide sharp nuclear 
details and allow good optimisation. The adjacent normal breast tissue was used as 


























DDR2 Vimentin SNAIL 1 
            
BMI            
   20-24.9 21 9, 9 145.0 (37.1) 11110.0 (4850.6) 6.7 (1.3) 66.2 (19.1) 2636.0 (1799.0) 5.2 (2.4) 1.2 (1.2) 5.5 (3.3) 2.2 (2.2) 
   30+ 25 8, 17 * 134.0 (29.1) 9507.3 (4099.0) 7.1 (1.3) 66.0 (19.1) 2839.0 (1596.0) 6.0 (2.3) 0.8 (0.8) 5.9 (3.2) 2.8 (2.4) 
            
Ethnicity            
   NZ European 40 13, 23 138.0 (34.2) 10023.7 (4556.6) 7.0 (1.3) 66.3 (19.2) 2755.4 (1747.0) 5.7 (2.4) 0.9 (1.0) 5.6 (3.3) 2.7 (2.3) 
   Maori 3 1, 2 157.9 (20.4) 13240.0 (4049.6) 6.4 (1.7) 66.8 (19.0) 2698.6 (1297.5) 4.6 (0.4) 1.7 (0.6) 4.7 (1.4) 3.3 (2.9) 
   Asian 3 2, 1 139.0 (29.8) 10112.0 (3980.9) 7.2 (0.7) 65.6 (21.4) 2674.0 (1402.0) 5.9 (2.9) 1.0 (1.0) 7.9 (3.7) 0.3 (0.6) 
            
Histo Type            
   Ductal NST 35 14, 21 138.9 (33.9) 10159.5 (4928.4) 6.8 (1.4) 64.9 (17.1) 2641.5 (1458.2) 6.0 (2.3) 0.7 (0.9) 6.0 (3.4) 2.4 (2.3) 
   Lobular 6 2, 3 146.9 (40.3) 10234.8 (3405.5) 7.2 (1.3) 75.5 (24.7) 3560.1 (2385.1) 4.5 (1.6) 1.8 (1.0) 3.9 (1.6) 2.7 (2.1) 
   Other 5 1, 2 134.0 (19.6) 10803.0 (2093.5) 7.3 (0.4) 65.2 (24.1) 2504.0 (2289.0) 4.7 (3.0) 1.6 (0.9) 5.5 (3.7) 3.4 (2.7) 
            
Nott. Prog. Index            
   3.4-5.4 32 12, 19 140.0 (32.4) 10283.0 (4382.6) 7.0 (1.3) 66.3 (18.8) 2797.0 (1617.0) 5.8 (2.5) 0.9 (1.0) 6.2 (3.4) 2.6 (2.4) 
   >5.4 14 5, 7 139.0 (35.9) 10138.0 (4863.8) 6.9 (1.4) 66.3 (19.6) 2630.0 (1861.0) 5.2 (2.1) 1.0 (1.1) 4.4 (2.4) 2.4 (2.1) 
            
Grade            
   2 15 5, 8 147.6 (28.9) 10927.8 (3853.5) 6.9 (1.2) 71.7 (22.2) 3094.5 (2019.0) 4.6 (2.4) 1.5 (0.9) 3.7 (2.1) 3.3 (2.1) 
   3 31 12, 19 135.0 (34.7) 9906.0 (4777.4) 7.0 (1.3) 64.2 (16.9) 2578.0 (1490.0) 6.1 (2.2) * 0.7 (0.9) 6.7 (3.3) 2.2 (2.4) 
            
Tumour Size (mm)            
   ≤20 mm 18 5, 14 146.0 (38.9) 10792.0 (4417.4) 6.7 (1.4) 68.9 (19.8) 3026.0 (1750.0) 5.5 (2.2) 1.1 (1.1) 5.6 (2.8) 2.7 (2.4) 
   20-50mm 22 11, 6 136.7 (28.8) 10225.4 (4826.5) 7.0 (1.2) 63.0 (17.1) 2408.0 (1504.9) 6.0 (2.7) 0.8 (0.9) 5.9 (3.8) 2.3 (2.2) 
   >50mm 6 1, 6 128.0 (29.3) 8361.5 (3498.8) 7.6 (1.4) 70.5 (22.9) 3148.0 (2091.0) 4.8 (1.5) 1.3 (1.4) 5.4 (2.9) 2.9 (2.6) 
(Table continued on 
next page) 
           
  
 
            
No. Nodes            
   0 26 11, 15 139.9 (32.4) 10147.3 (4507.4) 6.9 (1.3) 66.1 (19.0) 2776.7 (1550.0) 6.1 (2.4) 0.8 (1.0) 6.5 (3.6) 2.1 (2.0) 
   1-4 12 3, 6 143.8 (39.0) 11358.8 (5038.7) 7.1 (1.4) 67.3 (20.3) 2645.7 (1958.2) 5.0 (2.5) 1.1 (0.8) 5.0 (2.8) 4.2 (2.4) 
   >4 8 3, 5 131.0 (28.0) 8858.5 (3493.6) 6.8 (1.1) 65.4 (18.3) 2799.0 (1849.0) 5.1 (1.7) 1.3 (1.3) 4.0 (1.7) 1.7 (2.1) 
            
LVI            
   Yes  12 3, 6 139.0 (35.8) 10344.0 (5614.0) 6.8 (1.4) 69.1 (20.3) 3001.0 (1894.0) 4.6 (1.8) 1.2 (1.2) 4.5 (2.4) 2.7 (2.2) 
   No 34 14, 19 140.0 (32.6) 10202.0 (4105.8) 7.0 (1.3) 65.4 (18.5) 2656.0 (1613.0) 6.0 (2.3) 0.9 (0.9) 6.1 (3.4) 2.5 (2.3) 
            
ER Status            
   ER+ 23 8, 13 145.0 (31.5) 11146.0 (3887.0) 6.9 (1.1) 67.0 (19.8) 2793.0 (1757.0) 5.4 (2.4) 1.3 (0.9) 3.9 (2.3) 3.2 (2.4) 
   ER- 23 9, 13 133.9 (34.4) 9332.1 (4921.7) 7.0 (1.5) 65.7 (18.3) 2700.0 (1629.0) 5.9 (2.4) 0.6 (1.0) 7.5 (3.1) 1.9 (2.1) 
            
PR Status            
   PR+ 19 6, 11 141.0 (27.5) 10990.0 (3855.0) 6.9 (1.1) 68.4 (21.2) 2909.0 (1901.0) 5.3 (2.5) 1.6 (0.9) 3.6 (2.1) 3.5 (2.4) 
   PR- 27 11, 15 138.5 (37.0) 9710.8 (4873.0) 6.9 (1.4) 64.8 (17.2) 2632.2 (1524.9) 5.9 (2.2) 0.7 (1.0) 7.1 (3.2) 1.9 (2.0) 
            
HER2 Status            
   HER2+ 5 2, 3 132.0 (24.9) 11120.0 (5200.0) 7.1 (1.1) 65.5 (14.1) 2641.0 (1150.0) 5.9(2.1) 1.0(1.2) 4.0(1.4) 4.3(3.1) 
   HER2- 41 15, 23 140.2 (32.0) 10131.7 (4445.9) 6.9 (1.3) 66.4 (19.5) 2759.2 (1739.3) 5.6(2.4) 0.9(1.0) 5.9(3.4) 2.3(2.1) 
            
TNBC            
 23 9, 14 134.0 (34.4) 9332.1 (4921.6) 7.0 (1.5) 65.7 (18.3) 2700.0 (1629.0) 5.9(2.4) 0.6(1.0) 7.5(3.1) 1.9(2.1) 




Figure 2.1 Masson’s trichrome stain optimisation in human breast carcinoma samples using 
different types of Haematoxylin.  
 (A) Abcam Haematoxylin, (B) Gill’s Haematoxylin, (C) Krutsay’s Iron Haematoxylin. Magnification 
10x. Cell cytoplasm – red, nuclei – blue/black, collagen – blue. Inserts (magnification=40X oil) show 
cellular and nuclear details with arrowheads showing: (1) Cancer Associated Adipocyte (CAA), (2) 





Figure 2.2. Masson’s trichrome staining of a control section of normal human breast.  
Magnification=10x. Arrows show: (1) cell cytoplasm - red, (2) nuclei - blue black and (3) collagen - 
blue. Also shown in the picture are (4) unstained normal adipocytes. 
2.3.3 Cancer Associated Adipocytes (CAA)  
Figure 2.3 shows an example of how ROI were selected to study CAA at the tumour 
interface (IF) and within the tumour (Tm). As exemplified in Figures 2.3 and Figures 
2.4-2.6, we consistently observed the presence of adipocytes of smaller sizes at the 
invasive front of human breast tumours, as compared with adipocytes in adjacent 
normal breast adipose tissue. Within the tumour, CAA also appeared smaller and more 
scattered compared to their mature counterparts and were surrounded by collagen 
(Figures 2.4-2.6). Adipocyte diameter (p<0.001), area (p<0.001) and number (p=0.008) 
were all significantly decreased within the tumour (Tm) compared to at the tumour 





Figure 2.3. Masson's trichrome stained sections of human breast carcinoma showing 
representative example of selection of regions of interest (ROI) using Image J.   
Magnification 10x. Cell cytoplasm – red, nuclei – blue/black, collagen – blue. (A) IF – Invasive Front, 




Figure 2.4 Masson's trichrome stained examples of human breast carcinoma from three different 
specimens(A,B,C) showing difference in adipocytes size at the interface and within the tumour. 
Magnification 10x. Cell cytoplasm – red, nuclei – blue/black, collagen – blue. Figure shows (Ad) 




Figure 2.5 Masson's trichrome stained section of invasive front of human breast carcinoma 
showing phenotype of mature adipocytes and Cancer Associated Adipocytes (CAA) against a 
background of extensive collagen rich extracellular matrix and dense immune infiltrate.  
Magnification (A) 10x, (B) 20x, (C) 40x oil. Cell cytoplasm – red, nuclei – blue/black, collagen – blue. 
(A) Arrows show elongated CAA with concentrated deposition of collagen fibrils (B) Arrow shows CAA 
in single file along a collagen bundle. (C) Arrow shows CAA merging into a budding cancer cell nest 




Figure 2.6 Masson's trichrome stained section of human breast carcinoma depicting matrix 
remodelling and recruitment of cellular elements.  
Magnification (A) 10x, (B) 20x, (C) 40x oil. Cell cytoplasm – red, nuclei – blue/black, collagen – blue. 
(A) Arrows show (1) Collagen fibrils (2) CAA, (3) breast carcinoma cell nests and (4) immune cells. The 
same field of view at increasing magnification (20x and 40x oil, respectively). (C) Arrow shows collagen 




Figure 2.7 Comparison of CAA diameter (A), area (B) and number (C) at the tumour interface 
and within the tumour.  






2.3.4  Masson’s Trichrome staining for TACS   
Collagen deposition patterns were imaged and classified as Tumour-Associated 
Collagen Signatures (TACS) (Conklin et al., 2011) (Figures 2.8-2.10). TACS-1 was 
defined by deposition of wavy relaxed collagen fibrils that were most common in 
normal and early stage breast tumours (Figure 2.8A, 2.9, 2.10A). As tumours increased 
in size, collagen fibres appeared straighter and were aligned parallel to the tumour 
boundary (TACS-2) (Figure 2.8B, 2.9, 2.10B). Remodelling of the stroma progresses 
to the final stage, which is the reorientation of collagen such that multiple collagen 
fibres are bundled and aligned perpendicular to the tumour boundary (termed TACS-3) 
(Figure 2.8C, 2.9, 2.10C, 2.11). It was also observed that tumour cells appeared to 
preferentially invade along straightened, aligned collagen fibres, which may provide 




Figure 2.8 Masson’s trichrome staining showing representative examples of Tumour Associated 
Collagen Signatures (TACS) within breast tumour samples. 
Magnification = 20x. Cell cytoplasm – red, nuclei – blue/black, collagen – blue. Arrow heads show: (A) 
TACS-1 increased deposition of relaxed wavy collagen fibrils near the tumour lesion, (B) TACS-2 
straightened collagen fibrils aligned parallel to the tumour boundary, and (C) TACS-3 multiple stiff 




Figure 2.9 Masson’s trichrome stain showing all three of the archetypal Tumour Associated 
Collagen Signatures (TACS) in human breast carcinoma.  
Magnification = 20x. Cell cytoplasm – red, nuclei – blue/black, collagen – blue. TACS-1 relaxed wavy 
collagen fibrils (black arrow bottom right), TACS-2 straight collagen fibrils aligned parallel to the 
tumour boundary (black arrow top left), TACS-3 collagen fibrils oriented almost radially away from the 




Figure 2.10 Masson’s trichrome stain showing examples of different Tumour Associated Collagen 
Signatures (TACS).  
 Magnification 40x oil. Arrows show (A) TACS-1 soft relaxed collagen bundles, (B) TACS-2 straight 
collagen bundles tangential to the tumour epithelial cell cluster, and (C) TACS-3 stiff collagen bundles 




Figure 2.11 Masson’s trichrome stained section of human breast carcinoma showing TACS-3  
Magnification 64x oil. Cell cytoplasm – red, nuclei – blue/black, collagen – blue. Red arrows show 
collagen fibrils aligned at steep angles to malignant breast cancer cells (TACS-3). Also depicted with 




Figure 2.12 Masson’s trichrome stained section of human breast carcinoma showing TACS-3 
collagen and disseminating carcinoma cells migrating towards a nearby blood vessel.  
Magnification (A) 5x, (B) 10x, (C) 20x. Cell cytoplasm – red, nuclei – blue/black, collagen – blue. (A) 
Arrows show (1) collagen fibres, (2) breast carcinoma interface, (3) adipocytes and (4) blood vessel. (B) 
Arrow shows TACS-3 collagen fibres providing ‘highways’ for cellular elements to intravasate to the 
closest blood vessel. (C) Arrows show migration of tumour cells, CAA and immune cells in a single file 
pattern and in clusters. 
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2.3.5 Anti-collagen I stain 
Masson’s trichrome stains all types of collagen and is a ‘gold standard’ pan-collagen 
stain used in the Anatomical Pathology department of CDHB. Given that preliminary 
co-culture studies performed in our lab specifically showed increased secretion of 
collagen I by cancer-associated adipocytes, anti-collagen I antibody was used to stain 
for collagen I in our breast cancer cohort. 
After trying a range of primary antibody dilutions, good optimisation of 
immunostaining was achieved at 1:800 concentration, and this was used for all 
subsequent staining. Collagen I was generally localised in the ECM surrounding CAA 
(Fig 2.13). It was also consistently observed in the walls of blood vessels and skin, 
acting as internal controls. The extent, intensity and distribution of staining was 
heterogeneous. The topography of immunostaining was focal and denser at the interface 





Figure 2.13 Anti-collagen 1 antibody immunostained section of human breast carcinoma.  
Magnifications (A&B) 5x (C) 20x. (A) Negative control, (B) Positive control, (C) Black arrows indicate 
an increased expression of collagen 1 in the stroma surrounding CAA. 
 
2.3.6 Analysis of relationships among CAA parameters, Tumour-Associated 
Collagen Signatures (TACS) and clinicopathological variables. 
At both the interface and within the tumour there was the expected strong positive 
correlation between adipocyte diameter and area (P<0.01), and both these parameters 
were negatively correlated with adipocyte count (P<0.01) (see Appendix 1). Adipocyte 
count within the tumour was higher in grade 3 versus grade 1&2 tumours (Figure 2.14; 
p=0.022). Adipocyte diameter, area and number were not significantly different in 
tumours with TACS-1/2 versus TACS-3 (Figure 2.15). However, BMI was 
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significantly higher in patients with TACS-3 compared to TACS-1/2 tumours (Figure 
2.16; p=0.04), and this difference in BMI was due to increased weight (p=0.05), not 
height (p=0.94). Age at surgery showed weak positive correlations with number of 
nodes removed, number of positive nodes and the difference in adipocyte diameter 
between the interface and within the tumour, and a weak negative correlation with 
adipocyte area within the tumour (Appendix 1; p<0.05). No other associations were 
observed among adipocyte parameters, TACS or clinicopathological variables, 
including hormone receptor status (ER/PR/HER2), histo type, grade, lymphovascular 






Figure 2.14 CAA diameter (A), area (B) and number (C) in Grade 2 versus Grade 3 tumours, at 
the tumour interface and within the tumour.  




Figure 2.15 CAA diameter (A), area (B) and number (C) in TACS1/2 versus TACS3 tumours, at 
the tumour interface and within the tumour.  




Figure 2.16 Patient Body Mass Index (BMI), height (cm) and weight (kg) for breast tumours with 
TACS1/2 versus TACS3.  





Standard histopathological evaluation of breast cancer tissue traditionally focuses on 
the epithelial cell properties when determining the histological subtype, stage and grade 
of tumour to predict patient prognosis. However, a growing body of evidence has 
focused on the major influence of the tumour microenvironment on tumour behaviour, 
especially its pro-metastatic properties (Allen & Louise Jones, 2011; Joyce & Pollard, 
2009). Although, pathologists describe the qualitative characteristics of the stroma, it 
is not conceptualised as a quantitative marker of disease. Hence, in this study, the 
qualitative traditional histopathology review and quantitative image-based assays were 
integrated to investigate links between cancer-associated adipocytes (CAA) and 
stromal collagen structure and organisation in human breast carcinoma samples. 
2.5 The study cohort 
This study focused on breast tumours from post-menopausal women because recent 
epidemiological data have highlighted that obesity is associated with an increased 
frequency of post-menopausal breast cancer (Arnold et al., 2015; Calle & Kaaks, 2004; 
Ferlay et al., 2011), and with poor outcome in this subset of patients (Neuhouser et al., 
2015). The study included tumours from normal weight and obese women with either 
ER+ or hormone receptor negative (triple negative) tumours. This was because obesity 
is linked with worse outcome in patients with hormone receptor negative or TNBC 
(Phipps et al., 2008; Pierobon & Frankenfeld, 2013; Stoll, 2002). In addition, the 
literature has also highlighted that obesity-related changes in sex hormones and insulin-
like growth factor axis in ER+ breast cancers are linked to poor outcome (Alberti et al., 
2009; Hankinson et al., 1998; Hofbauer, 2002; Lueprasitsakul et al., 1990; Rosen & 
Spiegelman, 2014). Hence, these are important at-risk populations to include in the 
current study. 
2.5.1 Cancer-associated adipocytes (CAA) 
The breast tumour microenvironment is rich in adipose tissue, particularly in post-
menopausal women, and it is now well established that cancer-associated adipocytes 
(CAA) promote breast cancer progression and resistance to therapy (Rose & Vona 
Davis 2009; Dirat et al., 2011). Previous studies have reported the changes that occur 
in CAA in a breast cancer tumour microenvironment, including decrease in size, loss 
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of mature differentiation markers and phenotypic change to a more fibroblast-like 
morphology (Bochet et al., 2013; Dirat et al., 2011). The current study revealed a 
profound reorganisation of the adipose tissue at the tumour invasive front, and 
confirmed the decrease in size in CAA compared to mature adipocytes, and showed a 
further decrease in size in CAA within the tumour compared to CAA at the invasive 
front. The number of CAA also decreased within the tumour compared to at the invasive 
margin. Interestingly, CAA count within the tumour was higher in grade 3 than grade 
2 tumours. These findings align with previous in vitro studies that have shown CAA 
induce breast cancer cells to become more highly proliferative and invasive (Dirat et 
al., 2011, our own unpublished data). 
Interestingly, it was observed that fat cells also seemed to become smaller and 
elongated so as to merge into the cancer cells and move via collagen ‘highways’. This 
supports a previously proposed hypothesis about the origin of a subpopulation of 
Cancer Associated Fibroblasts (CAF), where they are suggested to originate from 
‘dedifferentiation’ of mature peritumoral adipocytes first into CAAs and then into 
fibroblast-like cells in the tumour microenvironment (Matsumoto et al., 2008; Motrescu 
& Rio, 2008; Park et al., 2011). Therefore, our results support the concept that cells 
with a fibroblast-like shape could be derived from mature adipocytes in a tumour-
context both in vitro and in vivo. 
2.5.2 Do CAA produce collagen? 
Previous studies, including unpublished in vitro studies from our own laboratory, have 
demonstrated that CAA secrete various types of collagen (Bochet et al., 2013; Halberg 
et al., 2008). In the current study, CAA were often observed embedded within and 
surrounded by collagen. Stromal collagen deposition was first overviewed by using 
H&E stain and later identified by using Masson’s trichrome stain as has been used by 
some other groups (Zhang et al., 2013). Although Masson’s trichrome selectively stains 
collagens, it cannot differentiate the collagen subfamily. To overcome this, an anti-
collagen I antibody was used to highlight abundant collagen I throughout the tumours 
and around CAA. However, from this immunohistochemical analysis it is not possible 
to state that CAA are producing the collagen. 
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2.5.3 Using TACS as a prognostic marker 
Provenzano et al. (2006) first defined three tumour-associated collagen signatures 
(TACS) as novel markers to locate and characterize tumours. A number of laboratories 
have used advanced technologies to study TACS in mice (Arendt et al., 2010; Boyd et 
al., 2011; Levental et al., 2009; Provenzano et al., 2006; Schedin & Keely, 2011). The 
use of multiphoton microscopy for research studies of human cancer tissues, including 
freshly biopsied tissues, has been reported by a number of groups (Cicchi et al., 2010; 
Pavlova et al., 2010; Williams et al., 2010). However, the common limitation with these 
studies was the expense, poor accessibility and time required for the analysis and to the 
best of my knowledge these approaches have not been implemented in routine clinical 
studies.   
Hence, the challenge was to translate this correlation to routine pathology workup, and 
the present study tried to overcome some of the aforementioned limitations by using 
less expensive substitutes to visualise collagen fibres along with cellular detail in H&E 
and Trichrome stains. The issue of size scale of analysis was kept in mind and paraffin 
embedded tissue slices from human breast cancer were used so as to have a sense of the 
spatial orientation of the cellular structures with respect to collagen deposition as a 
readout of the combined stromal influences. In addition, as collagen is a robust, 
abundant extracellular protein persisting even in poorly fixed tissues, it makes TACS a 
versatile and easily imaged biomarker with a potentially broad application in 
histopathology. Moreover, collagen has also been investigated in human ovarian 
(Kirkpatrick et al., 2007; Nadiarnykh et al., 2010), pancreatic (Drifka et al., 2015) and 
colorectal carcinomas (Ueno et al., 2014) where these cancers have been associated 
with dense aligned collagen suggesting that methods to image and characterize collagen 
changes could have broad relevance to several cancers.  
Previous studies have demonstrated aligned collagen fibres are functionally linked to 
invasion. Provenzano et al. used human carcinoma cell lines using 3D 
migration/invasion assays and observed that cells preferentially invade along 
perpendicularly aligned collagen fibres compared to randomly organized collagen 
(Provenzano et al., 2008 ). Moreover, Wang et al. (2007) demonstrated images of 
tumour cells crawling along straightened collagen fibres in murine models using second 
harmonic generation polarised light. In addition to effects on cell migration, an aligned 
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matrix is likely to be stiffer, and there is solid evidence that matrix stiffness promotes 
tumour cell proliferation (Paszek et al., 2005; Provenzano et al., 2009; Wozniak et al., 
2003). The present study found observations in line with these findings, where breast 
cancer cells appeared to move, singly and in clusters, towards the closest blood vessel 
using rigid, straightened collagen fibrils as stromal ‘highways. 
The current study showed characteristic collagen topology in human breast carcinoma 
as compared with normal breast, as each sample had an interface and normal breast 
tissue as internal control. TACS patterns were commonly observed in all the samples 
with a predominance of TACS2/3, suggesting the approach is robust and easy to 
implement in routine pathology practice. TACS-3 signatures were fairly common 
occurrence within those carcinomas that were TACS-3 positive, such that even with the 
subsampling we could find correlations. This is reassuring as pathologists only sample 
a microscopic part of the tissue in a clinical setting. However, since a tumour was 
labelled TACS-3 if any TACS-3 was observed within the tumour, this may have led to 
loss of statistical significance in the analyses. Observations from this study fit very well 
with previous reports of TACS-3 in mouse mammary carcinomas that discovered 
TACS-3 was not observed around the entire perimeter of each tumour region, but rather 
locally, and that localized sites of invasion are often noted in histopathology 
(Provenzano et al., 2006). In future studies, it may be better to score TACS at localized 
sites of invasion rather than using ROI throughout the tumour. 
2.5.4 Is TACS-3 more common when more CAA are present? 
Previous studies have demonstrated the presence of TACS-3 in tissue microarray 
samples from over 200 samples from human breast carcinoma patients. These samples 
were well characterised with respect to patients age, tumour size, histological subtype, 
tumour grade, lymph node status, ER/PR/HER2 receptor status. It was observed that 
the presence of TACS-3 is an independent prognostic marker for both DFS and DSS in 
patients with invasive breast cancer (Conklin et al., 2011). However, collagen 
alignment patterns (TACS types) in the context of spatial orientation to CAA and 
correlations with BMI were not performed. The current study has made some novel 
observations by trying to elucidate links between CAA and TACS-3, and further pairing 
these with poor patient outcome. Although this study showed TACS-3 was more 
prevalent in obese patients and was associated with higher grade (grade 3) tumours, this 
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study did not find TACS-3 was associated with increased CAA number (either at the 
tumour interface or within the tumour), or with poor patient outcome (i.e. reduced 
disease free survival or overall survival).  
2.6 Summary and conclusions 
Taken together, as expected and in keeping with the previous observations, extensive 
remodelling of the stroma was observed along the interface and within the tumour in 
human breast carcinoma specimens. CAA of decreasing size, area and numbers were 
seen at the interface as compared to the within the tumour. Increased density of collagen 
was observed in close proximity to CAA. Adipocyte count within the tumour was 
higher in grade 3 versus grade 1&2 tumours. BMI was significantly higher in patients 
with TACS-3 compared to TACS-1/2 tumours. It was also observed that cancer cells 
appeared to preferentially invade along the straightened, aligned collagen fibres, which 
may provide ‘highways’ for intravasation. 
To the best of my knowledge, the collagen alignment patterns (TACS) have neither 
been directly correlated with the presence of CAA, nor have their combined effects 
been explored in the context of tumour pathology and patient outcome. Hence, the key 
element of my study design was to pair the two stromal elements (TACS and CAA) and 
further analyse them with the clinicopathological patient data for the development of 
an ancillary histological tool to present new opportunities to diagnose, predict and treat 
breast cancer. 
Though no links were found between TACS and adipocyte measures, our data strongly 
support the concept that an intimate cross-talk is established between cancer cells and 
mature adipocytes at the invasive front of the tumour. Invading tumour cells are able to 
modify adipocyte phenotype, which in turn, stimulate cancer cells aggressive 
behaviour. The mechanism(s) responsible for the transition from mature adipocytes to 
CAAs still remain(s) unclear and warrant further investigations. The role of collagen 
alignment, the ECM, and various stromal cells in facilitating cell invasion links these 
predictors to underlying mechanisms of cell invasion. Further understanding of these 
processes should present new opportunities to diagnose, predict and treat breast cancer. 
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Chapter 3  
Collagen acting as a ligand to promote 
epithelial-mesenchymal transition in the 
breast tumor microenvironment 
3.1 Introduction 
There is emerging evidence that collagen plays a role in breast carcinoma 
progression. However, the mechanisms by which it exerts its malignant effects 
on breast carcinoma are not yet fully understood. Transwell co-culture studies 
performed in our research laboratory cultured breast cancer cell lines alone or 
together with mature human breast adipocytes. Analysis of the adipocyte 
secretome showed increased secretion of collagen, with about 2-fold higher 
secretion of collagen I by adipocytes co-cultured with breast cancer cell lines, 
compared to adipocytes cultured alone (personal communication, Dr Elisabeth 
Phillips, Mackenzie Cancer Research Group).  
Chapter 2 explored the possibility that collagen secreted by cancer-associated 
adipocytes (CAA) was facilitating breast cancer invasion and metastasis by 
deposition of collagen in the ECM, providing a mechanical ‘highway’ for cancer 
cell migration and metastasis. However, literature also suggests that collagen I 
may act through another mechanism to exert its pro-malignant effects. Collagen 
I acts as a ligand via its unique set of receptor tyrosine kinases (RTKs), called 
Discoidin Domain Receptors (DDR) to promote cancer progression. Both DDRs 
(DDR1 and DDR2) display broad collagen specificity and are activated by many 
different collagen types, with fibrillary collagens acting as ligands for both 
receptors (Shrivastava et al., 1997; Vogel et al., 1997). 
In normal tissues, DDR1 is constitutively expressed in epithelial cells and is 
activated by fibrillar and non-fibrillar collagens (Gonzalez, 2017). However, 
DDR2 is mainly activated by fibrillar collagen and is expressed only in 
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mesenchymal stromal cells, where it regulates ECM synthesis and promotes 
healing (Alves et al., 1995; Olaso et al., 2002; Valiathan et al., 2012). DDR2 
upregulation has been mentioned in various pathological conditions including  
malignancies, particularly breast cancer, where it is associated with poorer 
outcomes (Badiola et al., 2011; Barcellos-Hoff et al., 2013; Kim et al., 2015; Ren 
et al., 2013; Toy et al., 2015). Recently, Toy and colleagues discovered 
concordant dysregulation of expression in TNBC subtype with 
DDR1Low/DDR2High profile associated with worse overall survival (p=0.002) 
as compared to the luminal subtype (Toy et al., 2015). 
Zhang et al. (2013) took these observations to the next step and tied them up with 
the process of epithelial-mesenchymal transition (EMT) in breast cancer cells, 
which is thought to be the initial critical mechanism for metastasis. They 
proposed a working model, which posits that breast tumour microenvironmental 
signals activate DDR2 to induce breast cancer cell Snail1 nuclear localisation and 
EMT. The collagen I rich stroma activates DDR2, which regulates increased 
stability of Snail1 protein (by reducing ubiquitylation and increasing protein half-
life) leading to nuclear accumulation, which promotes breast cancer cell invasion 
and migration in vitro and metastasis in vivo (Ren et al., 2015; Zhang et al., 2013; 
Taube et al., 2013). 
My hypothesis for this study was that collagen I, secreted by cancer-associated 
adipocytes, acts via DDR2 to increase Snail1 protein levels and nuclear 
accumulation in breast cancer cells, thus promoting breast cancer cell epithelial-
mesenchymal transition and metastasis. Hence, the aim of the present study was 
to use trichrome staining and immunohistochemical labelling to visualize cancer-
associated adipocytes, collagen I and breast cancer cells expressing markers of 
EMT and/or mesenchymal phenotype in archived FFPE breast cancer tissue 
sections. The expression of immunohistochemical markers was then further 
analyzed together with clinicopathological data to look for associations with 




3.2 Methods and Materials 
3.2.1 Study design, case selection and ethics statement 
The study design, case selection and ethics statement have been described in 
sections 2.2.1 and 2.2.2. 
3.2.2 Immunohistochemistry 
Immunohistochemistry was performed on sequential sections from the archived 
FFPE samples obtained from CSBTC by using a standard biotin-avidin complex 
technique. FFPE samples (4µm) were deparaffinised and rehydrated, and 
endogenous peroxidase activity was quenched with 3% H2O2 for 20 minutes. 
Antigen retrieval was carried out for 3 minutes using a pressure cooker and 
sodium citrate buffer (pH 6.0). After staining the first two sequential tissue 
sections with H&E and Trichrome stain, respectively, the subsequent sections 
were sequentially incubated with a panel of primary antibodies in a fixed order 
as follows: collagen I (section 2.2.3.2) (Abcam MAb 2538, diluted 1:800), DDR1 
(Cell Signalling Technology MAb 5583, diluted 1:100 to 1:1000), DDR2 (R&D 
Systems clone 290814, diluted 1:100), vimentin (Cell Signalling Technology 
MAb 5741, diluted 1:100), Snail1 (Thermofisher Scientific MAb 20C8, diluted 
1:100) at 4C overnight in a humid chamber. A Dako Cytomation pen was used to 
draw barriers around the sections so as to contain and minimize use of the 
reagents. Next, incubation with rabbit-mouse link secondary antibody (R&D 
Systems) was performed for 1 hour at room temperature. Antibodies were then 
detected with HRP labelled polymer (Dako Cytomation) for 30 minutes at room 
temperature. Slides were further developed with diaminobenzidine (Envision 
Dako k-5361). Finally, the sections were counterstained with hematoxylin, 
dehydrated in an alcohol series, cleared and mounted using an automated system 
(Leica CV 500; Anatomical Pathology, CDHB). 
Each batch of staining included a negative control section with omission of 
primary antibody, and a positive control section of liver containing metastatic 
colorectal adenocarcinoma with fibrosis. 
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Overall good staining was achieved with all the antibodies except for anti-DDR1. 
Several dilutions were tried, and many attempts made with various trouble-
shooting measures as per the product data sheet, however, no staining was 
observed in the positive control section with anti-DDR1 antibody, and hence this 
was omitted from the final panel of primary antibodies used. 
3.2.3 Quantification of immunohistochemistry 
Immunohistochemical staining was evaluated by the candidate (MP) blinded to 
the clinicopathological data. These evaluations were then checked by an 
Anatomical Pathologist (Dr Andrew Miller, CDHB). 
3.2.4 Image analysis 
3.2.4.1 Selection of regions of interest (ROI) 
See section 2.2.3.3. 
3.2.4.2 Scoring immunohistochemical analysis 
Expression of collagen 1 was evaluated based upon its prevalence and density in 
the extracellular matrix and proximity to CAA. Expression of DDR2, vimentin 
and Snail1 are seen when cytoplasmic expression is detected in breast carcinoma 
(Wu et al., 2012). Expression of DDR2, vimentin, Snail1 were evaluated for  cell 
type and intracellular localisation of immunostaining; intensity of 
immunostaining (low, moderate, high), and; pattern of immunostaining (focal 
versus diffuse) (Volante et al., 2006). Focal epithelial cell staining was defined 
when less than 20% of cells expressed DDR2, vimentin or Snail1, and diffuse 
staining was defined when more than 20% of the epithelial cells expressed the 
protein. The same criteria were applied for the stromal cells. 
The expression of DDR2 hasn’t been systemically categorised in breast tissues 
previously. Hence, we applied a published scoring scheme to assess intensity of 
staining which was used to evaluate carcinoma biomarkers (Mackenzie et al., 
2011). Based on this system, the staining intensity was scored 0-3 as follows: 0, 
absent; 1, weak; 2, moderate; and 3, strong. The percentage of cells involved were 
scored 0-4 as follows: 0, 0%; 1, 1-10%; 2, 11-50%; 3, 51-80%; and 4, >80%.  The 
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expression score was calculated as intensity x percentage (score range 0-12). The 
presence of staining in immune cells was also recorded, as was the presence or 
absence of tumour necrosis (Salven et al., 1997). High scoring was defined as 
scores 9-12, moderate 5-8, and low scores were 0-4 (Mackenzie et al., 2011). 
3.2.5 Statistical analysis 





3.3.1 Anti-collagen I antibody 
See section 2.3.5 
3.3.2 Assessment of markers of EMT 
3.3.2.1 Anti-DDR2 antibody 
In the positive control section (Fig 3.1B), DDR2 was expressed consistently 
within the nuclei of metastatic colon epithelium, as well as in the mesenchymal 
cells in the surrounding stroma. 
Within the 46 cases of human breast carcinoma studied, DDR2 was found to be 
negative in normal breast cells as well as in malignant breast cancer cells (Fig 
3.2). Interestingly, there was a striking increase in protein expression of DDR2 
observed in the cytoplasm of mesenchymal cells in the stroma along the interface 
of the human breast carcinoma as shown in Fig 3.2A and B. The increased 
expression of cytoplasmic DDR2 was also observed in inflammatory cells as well 
as in the surrounding blood vessels. The pattern of staining was focal as well as 
diffuse. 
Statistical analysis of DDR2 expression and clinicopathological data showed a 
trend towards a positive correlation between DDR2 expression and adipocyte 






Figure 3.1 Representative examples of anti-DDR2 antibody immunohistochemistry on 
formalin-fixed paraffin embedded control sections.  
 (Magnification 20x). (A) Negative control section from human breast carcinoma. (B) Positive 
control section from human liver with metastatic adenocarcinoma from colon with fibrosis. Arrow 
heads show anti-DDR2 immunostaining in epithelial cells, stromal fibroblasts and immune cells. 







Figure 3.2 IHC images of representative examples of anti-DDR2 antibody on formalin-fixed 
paraffin embedded sections of human breast carcinoma (tumour interface).  
Arrow heads show (A) Striking increase in anti-DDR2 immunostaining in mesenchymal 






In search of achieving optimisation, a range of primary antibody dilutions were 
used (1:50, 1:100 and 1:200). Best visualisation was achieved at 1:100 and this 
was used in all subsequent staining as shown in Fig 3.3. In positive controls, 
vimentin was localised in the cytoplasm of liver hepatocytes, fibroblasts and 
immune cells. The intensity of expression was high, and pattern of expression 
was diffuse (Fig 3.3B). Figure 3.4 depicts examples of low (Fig 3.4B), moderate 




Figure 3.3 Representative examples of anti-vimentin antibody immunohistochemistry on 
formalin-fixed paraffin embedded control samples  
(Magnification 20x). (A) Negative control section from human breast carcinoma. (B) Positive 
control section from human liver with metastatic adenocarcinoma from colon with fibrosis. Arrow 
heads show high expression of vimentin in epithelial cells, stromal fibroblasts and immune cells. 










Figure 3.4 IHC images of vimentin protein intensity expression in human breast carcinoma 
samples  
(Magnification 20x). Examples show vimentin protein abundance: (A) absent, (B) weak, (C) 
moderate, and (D) strong staining.  
 
In this study, vimentin immunostaining was observed in all samples (high n=15, 
moderate n=9, low n=22), with a higher proportion of high vimentin 
immunostaining in TNBC. Vimentin immunostaining showed negative 
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correlations with adipocyte diameter (p=0.029) and area (p=0.013) at the tumour 
interface, adipocyte diameter (p=0.032) and area within the tumour (p=0.032), 
and a positive correlation with adipocyte count within the tumour (p=0.05). As 
expected, positive associations were found between high levels of vimentin and 
high tumour stage (p=0.07) and grade (p=0.02), and negative associations with 
ER positive (p=0.002) and PR positive (p=0.004) status. 
Fig 3.5 depicts a representative example of the conventional histopathological 
presentation of TNBC, with large central areas of necrosis surrounded by a rim 
of viable, basal-like cells that showed strong expression of vimentin 
 
Figure 3.5 IHC image of a representative example of triple negative breast cancer 
immunostained for vimentin. 
(Magnification 20x). Arrow heads show large islands of necrosis with a peripheral rim of viable 
tumour containing basal-like cells showing high expression of vimentin. 
Fig 3.6 shows a focus from human breast carcinoma interface with adipocytes of 
decreasing size in close proximity to vimentin-positive mesenchymal cells and 




Figure 3.6 IHC images of a representative example of the epithelial-mesenchymal transition 
(EMT) process in the human breast tumour microenvironment immunostained using anti-
vimentin antibody. 
(Magnification 64x oil). Arrow heads show: (A) healthy adipocyte, (B & C) dysfunctional 
adipocytes, (D) EMT derived stromal cell, and (E) immune cell infiltrate.  
Another interesting observation was the presence of strong expression of 
vimentin in surrounding immune cells in crown like structures (CLS) as 
exemplified in Fig 3.7. CLS are histological features in obese breast adipose 
tissue that are characterised by the accumulation of macrophages that surround 
dead and dying adipocytes. They may be markers of the chronic subclinical 
inflammation that is typical of obesity and is proposed as one of the mechanisms 




Figure 3.7 Immunohistochemical localization of vimentin in macrophages within Crown 
Like Structures (CLS) situated within adipose tissue surrounding a human breast 
carcinoma  
(Magnification 20x). Arrow heads show microscopic foci of adipocytes engulfed by vimentin-
positive macrophages forming extracellular trap-like structures.  
 
3.3.2.3Anti-Snail 1 antibody 
Optimal primary antibody dilution was achieved at 1:100 and, in the positive 
control, strong expression of Snail1 was noted in the cytoplasm of hepatocytes, 
stromal mesenchymal cells, as well as bile ducts and the endothelium of the blood 




Figure 3.8 Representative examples of anti-Snail1 immunohistochemistry on formalin-fixed 
paraffin embedded control sample.  
(Magnification 20x). (A) Negative control section from human breast carcinoma. (B) Positive 
control section from human liver with metastatic adenocarcinoma from colon with fibrosis. Arrow 
heads show immunolocalization of anti-Snail1 antibody in liver epithelial cells, bile ducts and the 
muscles within the wall of the blood vessels.  
As shown in Fig 3.9, a ‘differential pattern’ of expression of the antibody was 
seen, almost like a ‘gradient’ of strongest expression along the tumour interface 
decreasing to the weakest expression within the tumour centre. The staining 




Figure 3.9 IHC images of representative examples of anti-Snail1 immunostaining on 
formalin-fixed paraffin embedded samples of human breast carcinoma (tumour interface).  
(Magnification 20x). Differential antibody expression was found to be highest at the tumour edge 
relative to the tumour centre, forming a gradient of Snail1 protein expression. 
Towards the end of the experiment, an attempt was made to capture images of the 
same focus along all the sequential sections stained with different stains used 
H&E, Masson’s Trichrome, DDR2, Vimentin, and Snail so as to gain a visual 
comparison of the same structures stained with different staining techniques. This 




Figure 3.10 Morphology images of sequential slices of a human breast carcinoma captured 
by bright field microscopy using several staining techniques.  
 (Magnification 20x). (A) H&E stain and (B) Trichrome stain. Arrow heads showing (1) CAA, 
(2) collagen fibrils, (3) breast cancer cells, and (4) immune cells. (C) Anticollagen 1 antibody. 
Arrow heads indicate increased deposition of collagen around CAA. (D) Anti-DDR2 antibody. 
Arrow heads showing weakly positive focal areas of the upregulation of the antibody in cytoplasm 
of the epithelial cells along with stromal fibroblasts. (E) Anti-vimentin antibody showed strong 
immunoreactivity in the cytoplasm of clusters of carcinoma cells. (F) Anti-Snail1 antibody 
showed weakly positive diffuse staining in the cytoplasm of tumour cells. 
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There were no significant associations between Snail1 immunostaining and any 
of the clinicopathological parameters studies, although there was a trend towards 
a correlation between high Snail1 expression and TACS-3 collagen signature 
(p=0.06). 
3.3.4 Patient survival outcome 
No significant differences were observed in disease free survival (DFS) or overall 





DDR1 and DDR2 are types of collagen receptor tyrosine kinases which are 
activated by fibrillary collagen (Alves et al., 1995; Olaso et al., 2002). The 
collagen-binding DDR2 receptors activate signalling pathways that mediate EMT 
(Ren et al., 2013), and have roles in cancer progression in breast carcinoma 
(Valiathan et al., 2012). Cancer-associated adipocytes (CAA) modify the cancer 
cell characteristics/phenotype leading to a more aggressive behaviour (Bochet et 
al., 2013; Dirat et al., 2011). Further, transwell co-culture studies using breast 
cancer cell lines performed in our laboratory (Mackenzie Cancer Research 
Group) showed large amounts of collagen (particularly collagen I) were released 
by adipocytes when exposed to breast cancer cells (i.e. by cancer-associated 
adipocytes). Therefore, I hypothesised that CAA-derived collagen I may act via 
DDR2 receptors to promote breast cancer cell EMT and poor patient outcome. 
Regulation of epithelial cell plasticity during EMT is characterised by 
downregulation of commonly used markers such as cytokeratin with upregulation 
of mesenchymal proteins like vimentin (Barak et al., 2004). Based on these 
findings, an IHC pilot study was carried out on archived breast cancer tissue 
sections from the CSTBC to demonstrate the presence of EMT cells in breast 
cancer tumour microenvironment. 
This study supported a link between CAA, breast cancer EMT and poor patient 
outcome. However, it did not provide strong evidence to support a role for the 
collagen binding to DDR1 or DDR2 in CAA-driven breast tumour progression. 
The current study has extended previous work in our laboratory by Dr Elisabeth 
Phillips who co-cultured mature adipocytes with human breast cancer cell lines 
and used Mass Spectrometry to observe large amounts of collagen (particularly 
collagen1) released by adipocytes exposed to breast cancer cells. I performed IHC 
on our cohort of patients comprising of human invasive ductal carcinoma, lobular 
carcinoma and TNBC. Anti-collagen I antibody was used to assess collagen I 
content. Increased density of deposition was observed in the ECM especially 
around the CAA. Interestingly, increased collagen content in invasive ductal 
carcinomas has previously been reported (Zhang et al., 2013) and hence my 
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observations were supported by those of Dr Phillips and partially those with 
Zhang, although our work was unique because the density of collagen deposition 
was observed in a spatial context of CAA. 
Several studies have discussed mechanisms by which collagen elicits its 
malignant effects. Collectively, there is evidence that an increased amount of 
collagen acts as a ligand to initiate intracellular signalling pathways through 
specific receptors including DDR1 and DDR2 (Vogel, 1997; Shrivastava, 1997). 
These receptors have extracellular domains closely related to a Discoideum 
lectin, discoidin, required for cell aggregation. 
Toy has published a similar study looking at DDR1 and DDR2 in normal breast, 
DCIS and invasive carcinomas, but did not look at links between the expression 
levels in context of their links between obesity and CAA. They immune labelled 
DDR1 and DDR2 and found high DDR2 is associated with a high grade tumour, 
triple negative subtype and worse patient survival. Given these observations, anti-
DDR1 antibody optimisation was attempted in several dilutions on our cohort of 
invasive human breast cancer samples, but unfortunately very faint and uneven 
signals were detected on the positive control section. A possible explanation for 
this could be that five structurally different isoforms of DDR1 exist, which may 
activate separate signal transduction pathways (Valiathan, 2012; Zhang, 2013). 
However, at present no antibodies are available to detect these isoforms. This may 
mean that our subset of invasive carcinomas may have a different DDR1 isoform 
and that DDR1 in breast cancer are isoform dependent. Hence, future studies are 
needed to see the complexity of DDR1 regulation and its function in breast 
carcinoma. 
DDR2 is a tyrosine kinase receptor expressed in mesenchymal cells, which is 
preferentially activated by fibrillary collagens. These are the major components 
of ECM. Pathological DDR2 upregulation has been reported previously in 
cancers, including breast cancer. It was also associated with worse survival 
(Badiola et al., 2011; Barcellos-Hoff et al., 2013; Kim et al., 2015; Ren et al., 
2013; Toy et al., 2015). Of note, I found that a strikingly increased DDR2 
expression was observed in the stromal compartment and the adjacent fibroblasts 
especially along the leading edge of the tumour. This suggests that DDR2 
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upregulation is limited to cells closely interacting with the stromal 
microenvironment. This observation was in line with the observations made by 
Toy et al. (2015) and Ren et al. ( 2013). 
More interestingly, Maeyama and colleagues have reported that a striking 
increase in the expression of DDR2 and downregulation of  DDR1 (DDR2high/ 
DDR1low) was found in mesenchymal transformed breast cancer cells (Maeyama 
et al., 2008). Hence, we investigated the expression pattern DDR2 in the epithelial 
component of the human breast carcinoma samples. Anti-DDR2 antibody in a 
dilution 1:50 by R&D systems was used as was used by Zhang et al. in their study. 
However, my study used the Rapid Scoring System (Mackenzie et al., 2011) for 
quantification of IHC as compared to an H score that was used by Zhang in their 
study. I found that DDR2 expression was undetectable in the normal breast tissue 
as reported in the past (Zhang et al., 2013). However, unlike previous studies, I 
found only two tumours with moderate DDR2 expression and the rest (n=41) 
showed negative to mild DDR2 protein expression in the epithelial component of 
the tumour. One possible explanation for the heterogeneity observed in DDR2 
expression could be that DDR2 acts via another unknown pathway that needs 
further exploration. 
Intriguingly, the two tumours with moderate DDR2 protein expression appeared 
to have a lower mean adipocyte area at the tumour interface than the 41 tumours 
with low DDR2 expression (Spearman’s rho test; p=0.091). However, no 
significant association was found between DDR2 protein expression and any of 
the experimental or clinicopathological parameters studied. 
We next examined the expression pattern of an EMT marker - vimentin. Previous 
studies have examined EMT related markers for example vimentin, Snail1, Slug, 
Twist, N-cadherin and cytokeratins in breast tissue subtypes by IHC. EMT related 
biomarkers are more likely to be expressed in the basal type of breast cancer and 
related to the aggressive tumours (Fidler & Kripke, 1977; Liu et al., 2013). In the 
presence of a negative and positive control section for comparison, we found high 
expression levels of vimentin in n=15, moderate n=9 and low n=22, with a 
significantly higher proportion in TNBC, which is in consensus with Liu et al. 
However, Tsang et al failed to show any predictive role of the EMT marker 
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expression in prognosis (Tsang et al., 2013). They performed IHC in a large 
cohort of 1145 patients with breast cancer and evaluated the expression levels of 
E-cadherin and vimentin. Their data suggested that vimentin did not appear to be 
a good standalone marker for TNBC although was useful when used concordantly 
with E-cadherin. This observation could be relevant in the context of my research 
as vimentin was not used standalone but with a panel of other biomarkers such as 
DDR2, Snail 1 and collagen I to assess the presence of EMT in breast cancer 
cells. 
As far as I know, this was the first study that made some novel observations where 
vimentin scores were correlated with adipocyte parameters.  Using Spearman’s 
rho test it was seen that vimentin correlations were statistically significant with 
adipocyte diameter at interface (p=0.029), adipocyte area interface (p=0.013), 
adipocyte diameter tumour (p=0.032), adipocyte area tumour (p=0.030), and 
adipocyte count tumour (0.05). I also found strong correlations between high 
levels of vimentin and tumour parameters; chi-square tests showed that vimentin 
was associated with high T stage, grade, ER and PR status. This supports link 
between CAA, breast cancer cell EMT and poor patient outcome as previously 
shown by Dirat et al.  (2011), who showed CAA associated with partial EMT in 
breast cancer cells. 
Of note, I found strikingly increased expression of DDR2 in the stromal 
component of human breast carcinoma sections, especially along the interface in 
close proximity to CAA. This is also the active area of the tumour and rich in 
collagen as well as cells undergoing EMT. This could be ‘snapshot evidence’ to 
support my argument that collagen-binding DDR2 activates signalling pathways 
that mediate EMT, and that CAA modify the cancer cell 
characteristics/phenotype leading to a more aggressive behaviour. 
Identification of CLS was also made, which are macrophage extracellular trap-
like structures in mammary gland adipose tissue as described in recent studies 
(Mohanan et al., 2013; Mullooly et al., 2017). However, further research is 
needed to follow up these results with assessment of hormone levels and breast 
tumour pathology characteristics. Interestingly, we also found large areas of 
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necrosis lined by a rim of viable basal type cells with strong expression of 
vimentin antibody, which is a characteristic feature of the TNBC subtype. 
Human and mouse cancer cell line experiments and human pathology studies 
implicate Snail1 in breast cancer cell metastasis (Moody et al., 2005; Tran et al., 
2011). It has been shown to be present in tumour cells at the tumour-ECM stroma 
(Franci et al., 2006). Zhang et al. postulated that activation of collagen I receptor 
DDR2 regulates Snail1 protein stability in cells that have undergone EMT thereby 
promoting continued tumour cell invasion (Ren et al., 2013). In this study, we 
found an expression pattern of Snail1 in a ‘gradient’ with strong expression in the 
epithelial cells along the invasive edge of breast cancers, and comparatively low 
expression in the tumour centre. Hence, our results supported those of Franci. 
(2006), but not those of Zhang. (2013). Notably, there tended to be higher 
expression of Snail1 protein in tumours with TACS-3. The heterogeneity or 
localised distribution of Snail1 staining suggests multiple hypotheses. Given the 
fact that DDR2 expression was not found to be increased as postulated by 
previous studies (Ren et al., 2013; Toy et al., 2015), there could be other unknown 
pathways involved in the process of EMT that need further exploration. 
In summary, the majority of evidence linking breast carcinoma progression with 
EMT comes from cell lines and animal models. However, this study investigated 
human breast carcinoma samples to evaluate links between collagen I being 
secreted by CAA and increased levels of EMT markers and poor patient outcome 
(recurrence, DFS, OS). Although, I found strong correlations between high levels 
of vimentin, reduced adipocyte size and increased numbers (both at the interface 
and within the tumour) and tumour parameters associated with poor patient 
outcome (high number of positive nodes, T stage, grade and ER-/PR- status), no 
correlations were found with DDR2 and Snail1 protein. 
One of the primary limitations of this study was the small sample size, especially 
of the TNBC subgroup. The statistical analysis performed in this chapter must 
therefore be treated with caution. The other challenge in predicting EMT in 
practical clinical scenarios is that it is difficult to catch a ‘snap shot’ of this live 
event as the cells have either transitioned or are transitioning with hybrid or 
partial EMT forms. 
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Studying the process of collagen acting as a ligand via DDR1 and DDR2 
receptors and further activating the process of EMT in breast cancer cells is of 
major clinical importance. The knowledge that we have gained from the present 
study will improve our ability to view the process of EMT during cancer 
progression. The next logical step for future researchers could be performing a 
transwell co-culture study where breast cancer cells could be grown alone or with 
adipocytes in vitro, and measure expression of DDR1/DDR2, markers of EMT 
such as E-cadherin, vimentin, Snail1 and Slug. Understanding EMT and use of 
these techniques will further help in understanding and designing the best 








Breast cancer is one of the most highly diagnosed forms of cancer in NZ women 
and the second most common cause of death, with a significant toll on the 
healthcare system. Of note, New Zealand Māori women often present with 
multiple, highly invasive lesions with high risk of recurrence, metastasis and 
mortality, especially with a TNBC subtype. 
In breast cancer, it has been shown that modulation of adipose tissue-derived 
extracellular matrix (ECM) components, epithelial plasticity and epithelial-
mesenchymal transition (EMT) are crucial mechanisms leading to tumour 
initiation and progression. Given that the majority of breast carcinomas do not 
undergo the phenomenon of metastasis, other mechanisms facilitating tumour 
progression could be involved including a ‘tumour prone microenvironment’ (Hu 
et al., 2005) comprising of altered cell types as well as increased deposition of 
fibrillary collagens (Ren et al., 2013). Previous studies using animal tumour 
models have observed that fibroblasts with increased expressions of hepatocyte 
growth factor (HGF) or transforming growth factor beta (TGF-β) have the ability 
to promote tumour formation at diverse sites such as the stomach, prostate and 
breast (Bhowmick et al., 2004; Kuperwasser et al., 2005; Moses & Barcellos-
Hoff, 2011). These reports highlight the relevance of the tumour 
microenvironment in initiating the pathogenesis of the early steps of breast 
cancer. As the tumour advances to its later stages, cancer cells become more 
autonomous and evade the negative feedback mechanisms that would otherwise 
inhibit their growth, intravasation, migration, extravasation and colonisation to 
distant organs. 
It is of note that the tumour microenvironment of certain preferential organs for 
metastasis development often contains a rich fraction of adipocytes (Siclari et al., 
2006), such as breast. In addition, obesity has been suggested to be a sign of poor 
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prognosis in human breast carcinomas. With this background, a high number of 
obesity induced dysfunctional adipocytes have also been shown to have 
similarities in their molecular alterations to cancer-associated adipocytes (CAA). 
Although clues have started to emerge, the mechanisms by which dysfunctional 
adipocytes/CAA influence tumorigenesis remains largely unknown.  
The ECM undergoes constant homeostasis by the processes of deposition, 
remodelling and degradation in a normal and breast tumour microenvironment. 
In the presence of cancer cells this ECM homeostasis is disturbed not only by the 
tumour cells, but also by stromal components such as fibroblasts, macrophages, 
immune cells and their reciprocal interactions with the tumour cells. More 
recently, it has been shown that the tumour microenvironment in particular is also 
associated with altered post-translational modification, such as collagen cross-
linking, leading to the synthesis of a thick, dense and stiff microenvironment that 
is pro-tumourigenic (Cox & Erler, 2014). It has been seen that ECM remodelling 
is a contributor for cancer progression by clustering integrins and other receptors 
which lead to an activation of kinase receptor signalling pathways (Hastings et 
al., 2018), which consequently promote EMT as well as cancer cell migration and 
invasion (Dumont et al., 2013). Hence, induction of ECM remodelling 
accompanied by modulation of tumour microenvironment by the stroma 
components may provide a ‘permissive soil’ that would allow tumour cells to 
‘seed’ as well as escape from dormancy to invasion and metastasis (Barkan et al., 
2010). 
With this in mind, the current study was undertaken to further our knowledge of 
the dynamics of cell and microenvironmental properties that manage metastatis 
and cancer progression. The current study has extended previous work by our 
group, where in vitro studies showed that large amounts of collagen, especially 
collagen I was secreted by CAA. Previous studies have demonstrated over 
expression of collagen VI in vivo (Andarawewa et al., 2005; Iyengar et al., 2005; 
Park & Scherar, 2012) and collagen I (Halberg et al., 2008), however, previous 
studies have not investigated collagen I deposition in the context of CAA and 
human breast carcinoma specimens. Hence, our findings provide novel 
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observations to add to the existing literature about the breast tumour 
microenvironment. 
Given that collagen I density was highest around the areas of CAA and the 
literature has shown that collagen VI (COL6) is highly expressed in adipose 
tissue, upregulated in the obese state, and enriched in breast cancer lesions, it may 
be logical to argue that collagen I is also released from dysfunctional adipocytes 
during their interactions with breast epithelial cells. This study provided only a 
snapshot of a live phenomenon that requires further exploration. 
Even though a handful of biomarkers are present that guide and predict the 
treatment and outcome of breast cancer such as presence of ER, PR and HER-2 
receptors, there is a subset of patients who do have any of these markers (for 
example, a triple-negative breast cancer). Also, there are no markers to 
differentiate between the subset of patients in whom disease will progress from 
those whose disease will not progress. Therefore, discovery of novel predictive 
and prognostic markers is an advantage to refine the diagnostic process. 
It is known that mammographic density is one of the major risk factors for breast 
carcinoma (Boyd et al., 2002; McCormack, 2006), accounting for almost one 
third of cases, with increased collagen deposition as one of the biggest 
contributors for this (Alowami et al., 2003). Mammographic density itself doesn’t 
have the resolution to analyse the phenomenon of disease progression and is itself 
a poor predictor of disease recurrence (Park et al., 2009), and few studies have 
analysed the histopathological results in the context of collagen alignment 
patterns and patient outcome. 
The current study demonstrated that the aligned, straightened collagen fibrils 
designated as Tumour-Associated Collagen Signature (TACS-3) may provide 
‘highways’ for breast cancer cells for invasion and metastasis. This finding is 
similar to other studies that show collagen alignment promotes cell invasion 
(Provenzano et al.,2006; Provenzano et al., 2008). We found that cells invade 
along the aligned collagen fibres perpendicularly rather than random fibres. Wang 
et al. made interesting observations by presenting images of tumour cells moving 
along the straightened collagen fibres in breast cancer  in vivo (Wang et al., 2007). 
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Others have shown that metastasis is limited in an unaligned matrix (Provenzano 
et al., 2008). In addition, there is evidence to show that stiffness of the aligned 
matrix also facilitates tumorigenesis in tumour microenvironment (Provenzano et 
al., 2009; Wozniak et al., 2003; Paszek et al., 2005). 
TACS-3 as a marker for invasion and metastasis has potential application as 
collagen is preserved when tissue is subjected to many tissue processing 
approaches which include samples frozen in embedding medium,  samples that 
have not been embedded, and paraffin embedded formalin fixed tissue 
(Provenzano et al., 2006; Conklin et al., 2009). In addition to the Masson’s 
Trichrome stain that was used here, Picrosirius red stain also allows imaging of 
collagen structures using polarised light, especially when circularly polarised 
light is used to analyse fibres in various orientations. However, we used Masson’s 
Trichrome stain as it is a standard stain being used by the Anatomical Pathology 
Department here at Canterbury Hospital, and thus requires no additional 
polarising procedures. Regardless of the choice of stain used, the results obtained 
were important to collagen alignment pattern as long as fibres were discernible. 
The pathogenesis underlying the collagen alignment patterns as TACS-3 
orientation are not yet fully understood but could be a complex phenomenon 
involving more than one pathway as collagen is deposited, aligned and stiffened. 
All these processes are collectively termed ‘desmoplasia’, which is a stromal 
response to cancer formation that is promoted by the recruitment of fibroblasts 
and immune cells such as tumour associated macrophages (Leek et al., 2002). 
Tumour associated macrophages have also been suggested to control 
fibrillogenesis of collagen. Their presence has been shown to be associated with 
collagen topology in the terminal buds of developing mammary glands (Ingman 
et al., 2006; Pollard & Jeffrey 2008; Bingle et al., 2002) have shown that 
increased numbers of macrophages in breast tumour is associated with high 
hazard ratio and poor survival (Bingle et al., 2002). In addition, the literature also 
shows that macrophages facilitate invasion by initiating a paracrine signalling 
loop that promotes chemotaxis of carcinoma cells during invasion (Wyckoff et 




Menopause and age are known to be associated with higher grade tumours and 
metastatic disease. However, these factors are associated with decreased presence 
of collagen, this is in sharp contrast to the role that breast density in tumour 
progression (McDaniel et al., 2006; Ginsburg et al., 2008). This discrepancy can 
be explained by the cumulative life-time risk that these patients spend with high 
breast density even if this density decreases with advanced age. 
The current study also consistently observed a profound reorganisation of the 
adipose tissue at the tumour interface. Adipocytes of smaller size were seen along 
the invasive front of the human breast carcinoma as compared to normal breast 
tissue. Also, within the tumour, CAA appeared more scattered as compared to 
their mature counterparts and were surrounded by collagen. This study hence 
confirmed previous observations where dynamic desmoplastic events involving 
adipocytes were seen at the periphery of the primary tumours (Dirat, et al., 2010; 
Wang et al., 2012; Andarawewa et al., 2005). 
Collagen I may also exert its pro-malignant effects by acting as a ligand via the 
Discoidin Domain Receptor (DDR) signalling axis, that maintains Snail1 protein 
stability in breast tumour cells that have undergone EMT (Zhang et al., 2013). 
This mechanism could potentially contribute to the aggressiveness of breast 
cancer cells in women that have dense breasts, due to increased collagen 
deposition. EMT is a transient phenomenon that imparts cancer cells with a 
motile/aggressive phenotype by altering expression of molecular markers to a 
more mesenchymal phenotype. Most of the evidence about EMT has been 
derived from cancer cell lines and animal models, hence, human studies in this 
context have been limited. This is because it is a very transient and reversible 
phenomenon that quickly switches between Epithelial-Mesenchymal Transition 
(EMT) to Mesenchymal-Epithelial Transition (MET), with several intermediate 
forms that make it difficult to identify in human samples. Validating a set of 
biomarkers will be useful as this can characterise the subset of patients that would 
be at risk of development of drug resistance and metastasis. Hence, to further 
characterise the phenotype of EMT cells in human breast tumour 
microenvironment, we used immunohistochemistry with a panel of antibodies 
including anti-DDR1, anti-DDR2, anti-vimentin and anti-Snaill antibodies. 
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Although Toy in his recent article has shown an upregulation of anti-DDR1 
antibody in his cohort of human breast carcinoma, similar observations were not 
made in our experiment. Our different results could be due to using a different 
antibody, or to the fact that DDR1 exists as five different isoforms (Valiathan et 
al., 2012), with no antibodies currently available to analyse all of these.  
The current study found strikingly increased expression levels of DDR2 in the 
stromal component of human breast carcinoma samples, especially along the 
interface (IF) of the tumour. These observations are in line with observations 
made by previous studies (Ren et al., 2013; Toy et al., 2015). However, the 
current study did not observe increased DDR2 expression levels in the epithelial 
component of most breast cancers (n=41). Only 2 samples showed moderate 
DDR2 immunostaining. These results are in sharp contrast to the observations 
made by earlier studies (Ren et al., 2013; Toy et al., 2015), and may be due to 
DDR2 receptors acting via another unknown pathway that requires further 
investigation. Some interesting observations were made when DDR2 protein 
expression was studied in the context of adipocyte parameters. The two samples 
with moderate DDR2 expression levels also had a decreased mean adipocyte area 
at the tumour interface (IF) as compared to the tumours with low DDR2 
expression levels (n=41). This study did not have enough numbers to make firm 
conclusions, but these observations support our hypothesis that an intimate cross-
talk is established between adipocytes and cancer cells along the invasive front 
of the tumour, which results in modification of adipocyte phenotype and 
activation of the EMT programme in the tumour microenvironment. The 
mechanisms responsible for the transition of adipocytes to CAA remain unclear 
and require further exploration.  
The intermediate filament protein vimentin was also examined within our cohort 
of breast carcinoma patients. Less than half of the patients had low expression 
levels, one third had high expression levels, while nine of the 46 tumour samples 
had moderate expression levels. The strongest vimentin immunostaining was 
found in the TNBC subtype, which is in line with previous observations (Liu et 
al., 2013). It was also intriguing to note that vimentin immunoscores showed 
statistically significant associations with adipocyte parameters as well as high 
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tumour grade, stage and hormone status of the tumour. This further supports my 
hypothesis that links exist between CAA, breast cancer cell EMT and poor patient 
outcome. However, these results only provide a snap shot of a very subtle live 
event that requires further research. 
Snail1 protein was also studied in the same cohort of breast cancer patients. 
Snail1, as a candidate marker for EMT, was expressed in an interesting ‘gradient’, 
with strong immunostaining along the invasive front of the tumour and low 
immunostaining at the tumour centre. Hence, the results were concordant with 
those of Franci (Franci et al., 2016), while discordant with those of Zhang (Zhang 
et al., 2013). Our observations with Snail1 protein expression levels were quite 
similar to those with DDR2 in terms of staining being localised/heterogenous. 
This could be explained by the fact that both DDR2 and Snail1 exert their pro-
tumorigenic effects through an unknown pathway that requires further 
exploration. 
A major limitation of this study remained the small sample size, particularly of 
the TNBC subtype. The other challenge was that collagen fibrils providing 
highways to crawling breast cancer cells as well as the process of EMT are live 
events which are momentous, short lived and difficult to recapitulate as a 
scientific model. Hence, in this respect the current study only provided a snap 
shot of this living phenomenon that requires further exploration. 
Studying the premalignant effects of collagen as physical highways for tumour 
cells, as well as a ligand to promote EMT in breast cancer tumour 
microenvironment has major clinical implications. The knowledge acquired from 
the current study will increase our ability to understand these phenomena during 
breast cancer progression in clinical samples. The challenge going forward will 
be to assay the presence of robust biomarkers as early as possible, and to find 
ways to implement these in the routine clinical setting by pathologists, surgeons 
and oncologists. It is important to emphasise at this point that breast density and 
TACS alignment patterns have the potential for application in clinical settings as 
there is no need to change the pathology work flow and these can be readily 
stained and imaged in routine practice. Furthermore, collagen alignment patterns 
have not been paired up with the occurrence of EMT markers in the past, but it 
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would be logical to do so, as these can provide information about the underlying 
mechanisms that could predict the subset of patients at risk of developing of 
breast cancer cell invasion and metastasis. Clearly the list of validated markers 
needs to be expanded, and the antibodies used in immunohistochemistry need to 
be standardised, so they have broad clinical utility. 
The next logical step for future research would be to perform transwell co-culture 
studies where breast cancer cells could either be grown alone or with adipocytes 
in vitro and further measure expression of EMT markers such as DDR1/DDR2, 
E-cadherin, vimentin, Snail1 and Slug. These can then be standardised, measured 
and imaged by modern imaging techniques so as to gain an insight into the 
occurrence of these phenomenon in clinical samples. Understanding these 
processes will help us in providing customised therapies in future and give cancer 
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